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Abstract: Chronic liver dysfunction or injury is a serious health problem worldwide. Chronic liver
disease involves a wide range of liver pathologies that include fatty liver, hepatitis, fibrosis, cirrhosis,
and hepatocellular carcinoma. The efficiency of current synthetic agents in treating chronic liver
disease is not satisfactory and they have undesirable side effects. Thereby, numerous medicinal
herbs and phytochemicals have been investigated as complementary and alternative treatments for
chronic liver diseases. Since some herbal products have already been used for the management
of liver diseases in some countries or regions, a systematic review on these herbal medicines for
chronic liver disease is urgently needed. Herein, we conducted a review describing the potential role,
pharmacological studies and molecular mechanisms of several commonly used medicinal herbs and
phytochemicals for chronic liver diseases treatment. Their potential toxicity and side effects were also
discussed. Several herbal formulae and their biological effects in chronic liver disease treatment as
well as the underlying molecular mechanisms are also summarized in this paper. This review article
is a comprehensive and systematic analysis of our current knowledge of the conventional medicinal
herbs and phytochemicals in treating chronic liver diseases and on the potential pitfalls which need
to be addressed in future study.
Keywords: chronic liver disease; herbal medicines; molecular targets; Chinese medicine
herbal formulae
1. Introduction
Chronic liver diseases remain as one of the most serious health problems worldwide, which
may affect more than 10% of the world population [1]. Chronic liver diseases in the clinical context
describe pathological processes of the liver that involve a process of progressive destruction and
regeneration of the liver parenchyma, which will finally lead to cirrhosis and hepatocellular carcinoma
if left untreated. Among the various forms of chronic liver diseases, the most widely spread types
include viral hepatitis, alcoholic or nonalcoholic fatty liver disease, autoimmune hepatitis, cirrhosis
and hepatocellular carcinoma [2]. Excessive alcohol consumption, virus infection, obesity, diabetes
and drug-induced liver damage are the leading causes of these liver diseases [3–5]. Although there
have been remarkable progress in discovering treatment of chronic liver diseases over the last several
decades, most of the therapies still do not yield satisfactory outcomes in patients [6]. In view of the
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scarce treatment options and significant adverse effects incurred by conventional chemical agents,
novel prophylactic and therapeutic agents against chronic liver disease are urgently needed.
The use of herbal medicines can be traced back to more than 4000 years ago in ancient China.
Over recent decades, an increasing number of herbal products, including medicinal herbs and
phytochemicals, have been used for treating chronic liver diseases worldwide due to the high
abundance, long-lasting curative effects and few adverse effects. According to the previous studies,
medicinal herbs and phytochemicals could protect the liver by several mechanisms such as eliminating
virus, blocking fibrogenesis, inhibiting oxidative injury and suppressing tumorigenesis [7,8]. As a
chronic disease, most liver injuries need long-term treatment, thus, reducing side-effects of the therapy
is critical when developing novel hepatoprotective agents. Although most of the patients believe
that medicinal herbs and phytochemicals are natural and safe to be administrated without significant
toxicity or side effects, all medicinal agents including herbal medicines potentially have toxicity and
side effects. For safe use of medicinal herbs and phytochemicals, the potential side effects and toxicity of
these hepatoprotective herbal medicines should be seriously taken into consideration. In this paper, we
have reviewed several widely used and recognized medicinal herbs and phytochemicals in the present
treatment of chronic liver diseases, including but not limited to Coptis chinensis Franch (berberine),
Glycyrrhiza uralensis Fisch (glycyrrhizin), Silybum marianum (L.) Gaertn. (silymarine and silybinin),
Bupleurum chinensis DC (saikosaponins), Salvia miltiorrhiza Bunge (salvianolic acid) and Scutellaria
baicalensis Georgi (baiclin, wogonin). In addition, some Chinese medicine formulae for chronic liver
disease treatment have also been reviewed in this paper. Based on the time-honored clinical experience
in traditional Chinese medicine, it is believed that the multiple types of herbal or mineral ingredients
in the formula could have multiple therapeutic molecular targets in chronic liver disease treatment.
Both clinical trials and basic research of these herbal medicines were included to review the efficacy,
potential molecular mechanisms as well as the side effects or toxicity of the active ingredients. In order
to retrieve more recent publications about this topic, we conducted an updated search on the following
databases from 1990 (one Chinese database and four English databases): China Journals Full-Text
Database, MEDLINE, AMED (Allied and Complementary Medicine Database), EMBASE and The
Cochrane Central Register of Controlled Trials (CENTRAL). Herbs and phytochemicals for chronic
liver diseases treatment will be included in this review paper only if there are more than three papers
describing the in vitro or animal study of the particular subject, or if any paper describing clinical trials
on the subject. The inclusion criteria are stricter for traditional Chinese medicine formula as there
are so many herbal formulae that have been applied in chronic liver disease treatment in traditional
Chinese medicine. The included herbal formulae should have been studied by more than five original
researches as well as at least one clinical trial which have demonstrated the potential therapeutic effects
by this herbal formula in chronic liver diseases treatment.
2. Recent Research on the Roles of Herbs and Phytochemicals in Chronic Liver Disease Treatment
2.1. Herbs and Phytochemicals in the Treatment of Chronic Hepatitis
2.1.1. The Epidemiological and Pathological Characteristics of Chronic Hepatitis and Current
Therapeutic Strategy
Chronic hepatitis is the inflammation of the liver; the common causes of chronic hepatitis
include viral infection, autoimmune diseases and toxic substances such as drugs or alcohol. Viral
hepatitis is the most common liver diseases which may progress over time to fibrosis and cirrhosis [9].
The well-known pathogens for chronic viral hepatitis include Hepatitis viruses B (HBV) and Hepatitis
viruses C (HCV). At present, more than 30% of the world’s population is infected with the HBV
and 5% is considered as chronic HBV carriers. In some developed countries, due to the widespread
vaccination of HBV, Hepatitis C has become the most common cause of viral hepatitis since
the 1980s [10]. Hepatitis induced by toxins, such as alcohol or drugs, has also significantly increased
in recent years. For alcoholic hepatitis, recent studies have indicated that younger people, females,
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and binge drinkers have a higher incidence of suffering from this disease and are associated with
higher mortality rates [11]. A large number of drugs such as acetaminophen, antibiotics or other
chemical agents are also common causes of hepatitis. Age, genetic variability, female sex, and
previous drug-induced hepatitis are the key predisposing risk factors to drug-induced hepatitis [12].
The occurrence of autoimmune hepatitis is relatively rare; it is thought to have a genetic predisposition
and is more likely to occur in young women. Patients with autoimmune hepatitis are often
accompanied with other autoimmune diseases [13].
The specific mechanism of chronic hepatitis depends on the underlying causes of the disease.
In viral hepatitis, the immune system is activated by the hepatic virus, resulting in inflammation
and liver damage. In autoimmune hepatitis, the autoimmune disorder causes the abnormal immune
response against liver cells. In alcoholic hepatitis, the damage is usually found in association with
fatty liver which we will in a subsequent paragraph [14,15]. In general, the common characteristics of
chronic hepatitis are inflammation, necrosis and fibrosis in liver tissues. The macrophages (Kupffer
cells) and other liver-resident cells such as hepatic stellate cells and sinusoidal endothelial cells promote
the formation and emitting of pro-inflammatory signals of cytokines, chemokines, lipid messengers
and reactive oxygen species (ROS) and activate the inflammatory response that leads to hepatic cells
oncotic necrosis and apoptosis [16–18]. Apoptotic bodies derived from the damaged hepatic cells can
further activate Kupffer cells to secrete transforming growth factor beta 1, endothelial growth factor
and platelet-derived growth factor, which can promote the transformation of activated hepatic stellate
cells into myofibroblasts [19].
Currently, alpha-Interferon is the most widely used drugs for chronic Hepatitis B and C, although
only a few patients can respond to interferon therapy. So far, several novel anti-viral agents such as
nucleoside analogue have been applied to patients. However, these drugs cannot completely eradicate
the hepatitis virus, while at the same time they may induce significant adverse effects and drug
resistance [20]. For example, in patients with alcoholic hepatitis, pentoxifylline and prednisolone are
the first-line recommended therapy. Unfortunately, a large proportion of patients do not respond to
these drugs [21]. Budesonide with azathioprine may have potential therapeutic effects for autoimmune
hepatitis, but the durability of response and target population still need further study [22]. Due to the
limited therapeutic effect of conventional chronic hepatitis treatment, the use of complementary and
alternative medicine is expanding throughout the world. In some Asian countries, people have treated
chronic hepatitis with herbs or phytochemicals since ancient times; some herbal products have shown
remarkable therapeutic effects in both basic and clinical studies (Table 1).
2.1.2. Herbs and Phytochemicals in the Treatment of Chronic Hepatitis
Glycyrrhizin, an active component in Glycyrrhiza uralensis Fisch, has been used widely as a
folk medicine agent for hepatitis in China and Japan. In Japan, glycyrrhizin injection has been
used as an approved preparation for allergy inflammation since 1948 and for chronic hepatitis
since 1979 [23]. Recently, glycyrrhizin has been found to suppress HCV particle release as well
as the activity of phospholipase A2 (PLA2) [24]. As PLA2 has been proved to be related with HCV
particles’ release, the researchers concluded that suppression of Hepatitis C by glycyrrhizin may
be attributed to the reduced activity of PLA2. According to these studies, glycyrrhizin may be a
promising agent for Hepatitis C when it is used alone or combined with interferon. According
to the study by Fujisawa et al., glycyrrhizin also showed significant anti-inflammatory effects in
liver and other tissues. The mechanisms may be related to suppression of the cytolytic activity of
complement by activating both classical and alternative pathways. Further studies demonstrated
that glycyrrhizin suppresses the lytic pathway in which the membrane attack complex is formed [25].
In vivo studies also confirmed that glycyrrhizin can inhibit liver inflammation by enhancing the
secretion of interleukin-10 (IL-10) in concanavalin-A (Con A)-induced hepatitis mice model which
closely imitated the pathology of human autoimmune hepatitis. Further mechanism study revealed
that glycyrrhizin can modulate the function of dendritic cells in mouse with autoimmune hepatitis
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and further promote the production of anti-inflammatory cytokines such as IL-10 [26]. There has a
clinical case report on treating chemotherapy-induced HBV hepatitis with lamivudine combined with
glycyrrhizin for a non-Hodgkin lymphoma patient. The result showed that glycyrrhizin combined
with nucleotides’ analogue may be effective for controlling HBV replication in cancer patients [27].
Another clinical study in Europe also confirmed the therapeutic effect of glycyrrhizin in viral hepatitis.
Sixty-nine out of 72 treatment courses were completed in this study. In the placebo group, there were
no obvious changes of alanine aminotransferase (ALT) level. The mean percentage of ALT decrease
by the end of treatment was 47% in the six-time glycyrrhizin treatment per week group and 26% for
the three-time treatment per week group (p < 0.001). For the six-time per week treatment group, 20%
(three of 15) patients got normal serum ALT levels and for the three-time per week treatment group,
the result was about 10% (four of 41). No obvious side effects were detected in this study. The serum
ALT levels went up again when treatment stopped [28].
Silymarin is a mixture of flavonolignans extracted from Silybum marianum (L.) Gaertn (milk thistle
seeds) Major ingredients in silymarin include silibinin, isosilibinin, silicristin and silidianin. Silymarin
is a time-honored herbal remedy for chronic liver diseases worldwide. Silibinin is the major active
compound in silymarin, which has been widely studied for its hepatoprotective effects and anti-cancer
effects both in vitro and in vivo. The main problems in the clinical application of silymarin include poor
solubility and bioavailability. Recently, some modified derivatives of silymarin, such as the siliphos,
have been developed for liver disease treatment. This new chemically synthesized agent contains
lecithin which can significantly improve the solubility and bioavailability of silymarin [29]. Bonifaz et al.
explored the antiviral effects of silymarin, and their results showed that silymarin can down-regulate
the copy number of HCV core mRNA and protein expression. The antiviral mechanism of silymarin is
different from interferon which inhibits the JAK/STAT signaling pathway [30]. Silymarin can block
HCV entry and transmission by inhibiting the activity of microsomal triglyceride transfer protein and
suppressing apolipoprotein B production. However, it seems that silymarin may not decrease the
virus content in vivo, which has been proved by several clinical studies [31]. Mayer et al. developed
a systematic review for the therapeutic effects of silymarin in treating chronic viral Hepatitis B and
C, and the results demonstrated that silymarin can down-regulate serum transaminases in chronic
viral hepatitis patients, but the liver histology or serum viral content have not been affected by
silymarin [32]. A 12-month randomized controlled trial comparing the effects of silymarin with a
multi-vitamin placebo in chronic HCV patients also showed that silymarin at the recommended dose
has no better effect in clearing HCV RNA than the vitamin placebo. One hundred and fourty-one
patients were evaluated in this study. After two years, 64 patients in the silymarin treatment group
(n = 68) were HCV RNA positive and in 71 patients in the placebo group (n = 73) were HCV RNA
positive (p = 0.61). Sixty-five patients in the silymarin treatment group were anti-HCV positive
while 72 patients in the placebo group were anti-HCV positive (p = 0.56). [33]. Another clinical study
explored the immunomodulatory properties of oral silymarin in patients with Hepatitis C, and their
results revealed that silymarin can inhibit inflammation in vitro and in vivo. The mechanisms may be
associated with inhibition of T-cell proliferation and production by suppressing the pro-inflammatory
cytokine as well as up-regulating the anti-inflammatory IL-10 [34]. A meta-analysis demonstrated
that silymarin combined with other anti-viral drugs may be beneficial for the chronic Hepatitis B
patients [35]. Silibinin, the major active ingredient in silymarin, also exhibited the inhibitory effects
on Hepatitis C virus by blocking the clathrin-dependent trafficking. Silibinin can influence the
formation of both clathrin-coated pits and vesicles in liver cells and destroy the clathrin endocytic
pathway by interfering with the absorption and trafficking of transferrin [36]. A short-term pilot study
on 20 patients with chronically active hepatitis was carried out to assess the liver protective activity and
the antioxidant properties of a new silybinin phosphatidylcholine complex, and the results showed
that after treatment with this new silybinin complex, there was a remarkable reduction of serum
aspartate transaminase (AST) from 88.0 (95% CI 65.52–113.48) to 65.9 (95% CI 52.23–78.57) µ/L,
(p < 0.01), a decrease of ALT from 115.9 (95% CI 94.1–147.7) to 82.5 (95% CI 64.59–100.41) µ/L
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(p < 0.01), and a decrease of total bilirubin from 0.76 (95% CI 0.63–0.89) to 0.53 (95% CI 0.47–0.59)
mg/dL (p < 0.05) and of gamma-glutamyltranspeptidase from 51.4 (95% CI 35.69–67.11) to 41.3 (95%
CI 36.01–50.19) µ/L (p < 0.02). Decrease of Alkaline phosphatase was not obviously, from 143.4 (95%
CI 132.59–154.21) to 137.5 (95% CI 124.32–150.68) µ/L [37].
Phyllanthus niruri L is a subtropical plant widely distributing in China and South Asia, which has
been used as traditional medicines to treat chronic hepatitis as well as intestinal infections and kidney
disease [38–40]. The main active compounds in Phyllanthus niruri L including quercetin rhamnoside,
gallic acid, geraniin and quercetin glucoside have been identified and proved with the properties
of anti-bacterial, anti-viral and anti-hepatotoxic effects [41]. In recent years, several researches for
evaluating the anti-viral effects and safety of Phyllanthus niruri L have been conducted both in vitro
and in vivo. Lam et al., found that the ethanolic extract of Phyllanthus niruri L could suppress HBsAg
secretion and down-regulate the expression of HBsAg mRNA, with a mechanism that may be related
to up-regulation of annexin A7 protein [42]. A systematic review of 22 randomized trials (n = 1,947)
on using Phyllanthus niruri L for treating chronic Hepatitis B showed that Phyllanthus niruri L were
effective in clearance of serum HBsAg, HBeAg and HBV DNA without serious side-effects. When
compared with interferon (IFN) and placebo, the therapeutic effects of combination treatment of
Phyllanthus niruri L and IFN was better [43].
The rhizome of Polygonum cuspidatum Willd. ex Spreng. has been used as folk medicine for treating
chronic hepatitis, jaundice, cough, hyperlipidemia and arthralgia in some Eastern Asian countries for
thousands of years. This herbaceous perennial plant is widely distributed in the world and prefers to
grow in humid environment such as the valley or forest [44]. Recent pharmacological studies have
shown that Polygonum cuspidatum Willd. ex Spreng. has antiviral and hepatoprotective effects, and the
major active ingredients may include anthraquinones, resveratrol and polydatin [45]. According to a
recent meta-analysis review study, Polygonum cuspidatum Willd. ex Spreng. is one of the most frequently
used herbs in the traditional Chinese medicine for chronic hepatitis treatment [46]. In vitro studies
also confirmed that the water extract of Polygonum cuspidatum Willd. ex Spreng. at the concentration
of 30 µg/mL could suppress the expression of Hepatitis B e antigen (HBeAg). For the ethanol extract
of Polygonum cuspidatum Willd. ex Spreng., it could inhibit the production of HBV DNA at a low dose
(10 µg/mL) [47].
Bupleurum chinense DC is one of the most frequently used herbs for relieving exterior syndrome in
traditional Chinese medicine. When applying bupleurum decoction in combination with long-term
exercise training, rats with obstructive jaundice exhibited a significant reduction in inflammatory
cytokines expression, which in turn alleviated the liver hepatitis [48]. The leaf of Bupleurus
has been regarded as the useless part in Chinese medicine, but a recent study has demonstrated
that the saikosaponins extracted from Bupleurus leaves exhibit significant antioxidant effects and
hepatoprotective activity. In vitro study proved that the saikosaponins exhibited free radical scavenging
activity in diphenyl picryl hydrazinyl radical and can suppress the superoxide anion formation and
the activity of superoxide anion scavenging in liver cells [49]. There are many types of saikosaponin
and each type may have different biological effects in vivo. Previous study on saikosaponin C has
found that the HBV-infected liver cells cultured with saikosaponin C exhibited a remarkable lower
expression of HBV antigen in culture medium, and this antiviral effect was not due to the cytotoxicity
of saikosaponin C [50]. Saikosaponin B2 was also an effective antiviral agent. In vitro study confirmed
that saikosaponin B2 can suppress early HCV entry, such as neutralization of virus particles, inhibiting
viral attachment, preventing viral fusion, and finally blocking HCV infection of primary human
hepatocytes [51].
Salvia miltiorrhiza Bunge, also known as Chinese sage, has been widely used for the treatment of
cardiovascular and cerebrovascular diseases. Recent studies found the Salvia miltiorrhiza Bunge can
increase blood flow into the liver to reduce the potential damage by clearing the harmful substance
in the liver. Active ingredients of Salvia miltiorrhiza Bunge can also exert hepatoprotective effect from
CCl4-induced liver injury in rats. The protective effect may be due to inhibition of NF-kB and p38
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signaling in liver Kupffer cells [52]. Treatment of chronic iron-overloaded mice with Salvia miltiorrhiza
Bunge will improve the hepatic morphology, decreasing iron deposition as well as inhibiting the
expression of type I and type III collagen, TGF-beta mRNA, and increase the expression of matrix
metalloprotein-9 (MMP-9) mRNA in the liver. Moreover, Salvia miltiorrhiza Bunge treatment can
decrease malondialdehyde content as well as increase glutathione (GSH) content and superoxide
dismutase (SOD) activity while it reduced expression of TNF-alpha, IL-1alpha and caspase-3 [53].
Matrine and oxymatrine are both alkaloids with antiviral and anti-inflammation effects, which can
be isolated from the herb of Sophora flavescens Aiton. Ma et al. found that the single use of oxymatrine
(100 mug/mL), matrine (200 mug/mL), and the nucleoside analogs lamivudine (30 mug/mL) did
not show any inhibition effects on the content of HBsAg, HBeAg, and HBV-DNA in culture media.
However, the combination of lamivudine (30 mug/mL) with oxymatrine (100 mug/mL) or matrine
(100 mug/mL) can significantly suppress the content of HBsAg, HBeAg, and HBV-DNA, the
effects of combination treatment were even more remarkable than that from using lamivudine
alone at 100 mug/mL [54]. A recent study has analyzed the molecular mechanisms underlying
matrine’s anti-inflammatory effects in hepatic cells. The results found that matrine could increase
the concentration of nitric monoxide (NO) in culture supernatant of rat intestinal microvascular
endothelial cells (RIMECs) in a dose-dependent manner and up-regulate the endothelial nitric oxide
synthase (eNOS) concentration, which further improves the vasomotion in liver tissue. Additionally,
matrine reduced the secretion of IL-8, IL-6, and sICAM-1 induced by lipopolysaccharide (LPS) in
RIMECs. These results indicated that matrine could inhibit inflammation in liver and might be
beneficial for patients with hepatitis [55]. Yao et al. investigated the anti-HBV immunomodulatory
mechanism of oxymatrine in vitro. Their results showed that oxymatrine could activate the peripheral
lymphocytes and induce antiviral cytokine secretion. Pretreatment with oxymatrine could modulate
toll-like receptor 9(TLR9) signal pathway and promote the immune function of the TLR9 ligand against
virus [56].
Periplocoside A (PSA), a pregnane glycoside, is a new phytochemicals isolated from
P. sepium Bge which is widely used for treating rheumatoid arthritis in traditional Chinese medicine.
A recent study has examined the protective effects of PSA on T cell-mediated hepatitis induced by
concanavalin A (ConA) in murine model. Pretreatment with PSA significantly ameliorated liver
damage induced by ConA, the secretion of interleukin (IL)-4, interferon (IFN)-gamma and serum
alanine transaminase (ALT) levels were dramatically decreased, which further inhibited the hepatocyte
necrosis and protected the liver function in vivo. In vitro studies demonstrated that PSA suppressed
the secretion of inflammatory cytokines such as IL-4 and (IFN)-gamma produced by Natural killer
T cells upon stimulation with anti-CD3 mAb or α-galactosylceramide. In addition, no obvious toxicity
has been observed both in vitro and in vivo with PSA treatment. These results suggested that the
new phytochemicals PSA may have therapeutic potential for treating human autoimmune-related
hepatitis [57,58].
Baicalin, which is extracted from Scutellaria baicalensis Georgi, was proved to be able to protect
hepatocytes from oxidative stress by up-regulating both liver fatty acid binding protein expression
and activity of intracellular SOD and GSH [59]. Animal experiments confirmed that baicalin presents
anti-inflammatory, anti-oxidant, and anti-apoptotic effects, which offered its hepatoprotective effects
against hepatocellular ischemia/reperfusion-induced injury [60]. Wan et al. found that 50-day
treatment of the baicalin-containing diet (0.25% and 1%) also exhibited protective effects on liver
injury in iron overload mouse, the mechanism of which may be associated with the iron chelation
and antioxidant activities of baicalin [61]. Baicalein, another active compound isolated from Scutellaria
baicalensis Georgi, may be a promising agent for liver injury. According to a recent study, it can accelerate
liver cells’ regeneration by modulating IL-6 and TNF-alpha mediated signaling pathways [62]. Another
study found that the molecular mechanisms involved in baicalein-inhibited apoptosis of liver cells
were the protective effect on mitochondria, inhibition of the release of cytochrome c, decrease of the
Bax/Bcl-2 ratio, and suppression of the phosphorylation of NF-kB, JNK and ERK [63].
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Schisandra chinensis (Turcz.) Baill is a frequently used herbal medicine in China, where it has a
common name Wuweizi (five-flavor berry). According to the theory of traditional Chinese medicine,
Schisandra chinensis (Turcz.) Baill can supplement Qi and promote the production of body fluid.
Modern pharmacological studies confirmed that Schisandra chinensis (Turcz.) Baill may regulate the
body's humoral balance, promote cell-mediated immune responses and has anti-HBV properties [64].
Xue et al. isolated and investigated seven unknown lignans and a schischinone, together with several
known lignans from the fruits of Schisandra chinensis (Turcz.) Baill. Their study found that two lignans
from the Schisandra chinensis (Turcz.) Baill exhibited significant anti-Hepatitis B virus activity by
suppressing HBV DNA replication without obvious cell toxicity on hepatic cells [65]. Schisandrin
B, a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis (Turcz.) Baill,
has shown therapeutic efficiency for the treatment of hepatitis. The anti-inflammatory mechanisms
of Schisandrin B were investigated by Checker et al. The results showed that Schisandrin B can
induce nuclear translocation of redox sensitive nuclear factor erythroid-derived factor 2-related factor
(Nrf2) and increase the transcription of Heme Oxygenase-1(HO-1). Schisandrin B can also inhibit the
nuclear translocation of NF-kB in activated lymphocytes and suppress the expression of downstream
inflammation-related genes [66].
Astragalus membranaceus (Fisch.) Bunge has been one of the most widely used herbs in China for
thousands of years. According to the traditional Chinese medicine theory, it could increase metabolism,
improve the functions of lungs and the gastrointestinal tract, promote wound healing and provide
fatigue relief. The main active compounds in Astragalus membranaceus (Fisch.) Bunge are flavonoids
and saponins, such as calycosin, formononetin, astragaloside, and calycosin-7-Obeta-D-glucoside [67,68].
Modern researches have shown that Astragalus membranaceus (Fisch.) Bunge could modulate
immunologic system, inhibit virus growth and suppress cancer proliferation [69,70]. A recent study
has indicated that Astragalus membranaceus (Fisch.) Bunge has potential therapeutic effects in patients
with viral hepatitis. In vivo studies showed that Astragalus membranaceus (Fisch.) Bunge could suppress
duck HBV DNA replication. The liver pathological changes in duck viral Hepatitis B models with
Astragalus membranaceus (Fisch.) Bunge treatment were also milder than the control group. Clinical
study was conducted by the same group, in which Astragalus membranaceus (Fisch.) Bunge was used
for treating 116 patients with chronic viral hepatitis while 92 patients were given regular antiviral
agents. The proportion of negative seroconversions of HBeAg and HBV DNA were significantly higher
in the Astragalus membranaceus (Fisch.) Bunge group than in the control group (p < 0.01 and p < 0.05
respectively). These results showed that the clearance of serum HBeAg and HBV DNA was better
in Astragalus membranaceus (Fisch.) Bunge treatment group [71]. Further studies have identified that
the active ingredients in Astragalus membranaceus (Fisch.) Bunge for inhibiting HBV activities may be
triterpenoid saponin [72].
Table 1. Herbs and phytochemicals in chronic hepatitis treatment.
Herbal Medicines
(Herbs or
Phytochemicals)
The Sources of
Herbal Medicines Type of Study
Biological Effects and
Molecular Mechanism Reference
Glycyrrhizin Root of Glycyrrhiza
uralensis Fisch
In vitro
Suppression of Hepatitis C by
decreasing the activity of
phospholipase A2.
[24]
In vivo Suppressing the cytolyticactivity of complement. [25]
Clinical study
Enhancing the secretion of
IL-10 by dendritic cells. [26]
Controlling HBV replication. [27]
Decreasing serum ALT. [28]
Silibinin Fruits of Silybummarianum (L.) Gaertn
In vitro Inhibiting HCV by blocking theclathrin-dependent trafficking. [36]
Clinical study
Decreasing the secretions of
ALT, AST and alkaline
phosphatase in patients with
chronic active hepatitis.
[37]
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Table 1. Cont.
Herbal Medicines
(Herbs or
Phytochemicals)
The Sources of
Herbal Medicines Type of Study
Biological Effects and
Molecular Mechanism Reference
Saikosaponin C,
Saikosaponin b2
Root of Bupleurum
marginatum Wall. ex
DC
In vitro
Decreasing HBV antigen in
culture medium. [50]
Suppressing early HCV entry. [51]
Matrine,
Oxymatrine
Root of Sophora
flavescens Aiton
In vitro
Improving the effect of
lamivudine on suppressing the
secretion of HBeAg in
combination with oxymatrine
or matrine.
[54]
In vivo
Improving the vasomotion in
liver tissue by increasing the
concentration of NO in culture
supernatant of rat intestinal
microvascular endothelial cells
and up-regulating the
eNOS concentration.
[55]
In vivo
Activating the peripheral
lymphocytes and inducing
antiviral cytokine secretion by
regulating TLR9
signal pathway.
[56]
Periplocoside A Bark of Periplocasepium Bunge In vitro and in vivo
Ameliorating autoimmune
hepatitis induced by ConeA by
decreasing the secretions of
(IL)-4, IFN-gamma and ALT.
[57]
Baicalin, Baicalein Root of Scutellariabaicalensis Georgi
In vitro
Protecting hepatocytes from
oxidative stress by
up-regulating both liver fatty
acid binding protein expression
and activity of intracellular
SOD and GSH.
[59]
Anti-inflammatory,
anti-oxidant, and anti-apoptotic
in hepatic cells.
[60]
In vivo
Iron chelation and antioxidant
effects in iron overload liver. [61]
Accelerating liver cells
regeneration by modulating
IL-6 and TNF-alpha mediated
signal pathways.
[62]
In vitro
Inhibiting apoptosis in liver
cells by the protective effect on
mitochondria, inhibiting the
release of cytochrome c,
decreasing the Bax/Bcl-2 ratio,
and inhibiting the
phosphorylation of NF-kappaB,
JNK and ERK.
[63]
Schisandrin B Fruit of Schisandrachinensis (Turcz.) Baill In vitro
Anti-inflammation in liver by
inducing nuclear translocation
of Nrf2 and increasing the
transcription of HO-1.
[66]
Silymarin
Flavonolignans
mixture from the
fruits of Silybum
marianum (L.) Gaertn.
In vitro
Down-regulating the HCV core
mRNA and protein expression. [30]
Blocking of HCV entry and
transmission by inhibiting
microsomal triglyceride
transfer protein activity,
apolipoprotein B secretion, and
infectious virion production
into culture supernatants.
[31]
Clinical study
Decreasing serum
transaminases in patients with
chronic viral hepatitis, but not
affecting viral content in vivo.
[32,33]
Inhibiting inflammatory by
suppressing the
pro-inflammatory cytokine and
up-regulating the IL-10.
[34]
Salvia miltiorrhiza
Bunge
Aqueous extract of
root and rhizome of
Salvia miltiorrhiza
Bunge
In vivo
Reducing inflammation in the
liver by inhibition of NFkappaB
and p38 signaling.
[52]
Improving the hepatic
morphology, decreasing iron
deposition as well as inhibiting
the expression of type I and
type III collagen, TGF-beta
mRNA, and increasing the
expression of MMP-9 mRNA in
the liver.
[53]
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Table 1. Cont.
Herbal Medicines
(Herbs or
Phytochemicals)
The Sources of
Herbal Medicines Type of Study
Biological Effects and
Molecular Mechanism Reference
Bupleurum chinense
DC
Aqueous extract of
root or leaf of
Bupleurum chinense
DC
In vitro
Scavenging free radical activity
and suppressing the
superoxide anion formation.
[49]
In vivo Reducing inflammatorycytokine expression. [48]
Polygonum
cuspidatum Willd. ex
Spreng.
Ethanol extract of
rhizome of Polygonum
cuspidatum Willd. ex
Spreng.
In vitro
Suppressing the expression of
HBeAg and the production of
HBV DNA.
[47]
Schisandra chinensis
(Turcz.) Baill
Aqueous extract of
fruit of Schisandra
chinensis (Turcz.) Baill
In vitro
Anti-Hepatitis B virus activity
by suppressing HBV DNA
replication.
[65]
Phyllanthus niruri L
Aqueous extract of
whole plant of
Phyllanthus niruri L
In vitro
Inhibiting HBsAg secretion and
HBsAg mRNA expression by
up-regulation of annexin A7.
[42]
Clinical study Clearance of serum HBsAg,HBeAg and HBV DNA. [43]
Astragalus
membranaceus
(Fisch.) Bunge
Aqueous extract of
root of Astragalus
membranaceus (Fisch.)
Bunge
In vivo Suppressing duck HBVDNA replication. [72]
Clinical study
Clearance of serum HBeAg and
HBV DNA in chronic viral
hepatitis patients.
2.2. Herbs and Phytochemicals in the Treatment of Fatty Liver Disease
2.2.1. The Epidemiological and Pathological Characteristics of Fatty Liver Disease and Current
Therapeutic Strategy
Fatty liver disease, or steatosis, is a reversible pathological process wherein large vacuoles of
triglyceride fat accumulate in liver cells. Fatty liver disease is usually induced by excessive alcohol
consumption or metabolic disorders such as obesity, insulin resistance and dyslipidemia [73]. Alcoholic
fatty liver (AFL) refers to the alcohol-related steatosis while nonalcoholic fatty liver (NAFL) means the
original cause of steatosis is not alcohol. In Western countries, fatty liver disease is the most common
liver disease, the prevalence of which ranges from about 20%–60% [74]. In 1992, some researchers in
Italy started the Dionysos Study that intended to evaluate the prevalence and incidence of chronic liver
disease in two communities of Northern Italy. According to their results, 45% of the residents had fatty
liver disease identified by liver ultrasonography. As fatty liver diseases cannot be distinguished at
liver biopsy, normally, their distinction depends on alcohol consumption. Using a cut-point of 20 g/d
for ethanol consumption, about 25% residents had NAFL while 20% had AFL [75]. In patients with
NAFL, approximately 30% patients will progress to non-alcoholic steatohepatitis (NASH). In those
with NASH, approximately 20% will further progress to cirrhosis, in which the histological lesions
of the liver are irreversible. For patients with AFL, nearly 20%–40% of these patients will progress to
alcoholic steatohepatitis (ASH). Of those with ASH, approximately 40% will develop cirrhosis [76].
Defects in fatty acid metabolism are responsible for the initial stage of fatty liver disease, which
may lead to lipid overstorage in the liver. For AFL, alcoholism may damage mitochondria and other
cellular structures, and further leads to cellular fatty acid metabolism disorder. For NAFL, insulin
resistance and other metabolism disorder induced the lipid storage and progress to steatosis. In both
AFL and NAFL, steatosis will sensitize the liver tissue to the induction of inflammation by oxidative
stress and will further develop steatohepatitis [77]. Actually, only a part of patients with steatosis will
progress to steatohepatitis, and the mechanisms are still unclear. The inflammation and a high degree
of steatosis will induce hepatocyte necrosis, lipid peroxidation and activation of stellate cells, which
play an important role in liver fibrosis [78].
The therapeutic strategy for fatty liver depends on its cause, treating the underlying cause at
an early stage of steatosis may reverse the process and inhibit steatohepatitis. Thus, strict restriction
of alcohol consumption and avoiding high calorie containing foods are important interventions for
patients with fatty liver. For those with early stages of non-alcoholic fatty liver disease, a gradual
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weight loss is the only solution for preventing disease progression. Conventional medications such as
ursodeoxycholic acid, insulin sensitizers, antioxidants or lipid-lowering drugs for decreasing insulin
resistance, hyperlipidemia, and inducing weight loss may have certain therapeutic effects on pure
steatosis without inflammation. For advanced patients with steatohepatitis, there are still no effective
treatments [79,80]. According to recent studies, some herbal products seemed to have positive effects
on this potentially reversible disease. Both basic and clinical studies suggested that herbal medicines
may have modest benefit for fatty liver disease treatment (Table 2).
2.2.2. Herbs and Phytochemicals in the Treatment of Fatty Liver Disease
Berberine is a quaternary ammonium salt isolated from the plant of Berberis such as Coptis
chinensis Franch, which is one of the 50 fundamental herbs used in traditional Chinese medicine.
The alkaloids in Coptidis Rhizoma aqueous extract (CRAE) were found to be effective in reducing
triglyceride (TG) accumulation in the FFA-induced hepatic steatosis in liver cells. Berberine has
been confirmed as the major compartment in inhibition of TG accumulation [81]. Berberine can also
enhance insulin resistance of nonalcoholic fatty liver disease by increasing the expression of insulin
receptor substrate-2 (IRS-2) and regulating the insulin signaling pathway [82]. Xue et al. found that
the berberine-loaded solid lipid nanoparticles (BBR-SLNs) can relieve hepatosteatosis in db/db mice
by suppressing lipogenesis and promoting lipolysis in the liver. Further study of the mechanisms
revealed that BBR-SLNs can inhibit the expression of lipogenic genes such as stearoyl-CoA desaturase
(SCD1), fatty acid synthase (FAS), and sterol regulatory element-binding protein 1c (SREBP1c), and
increase the expression of lipolytic gene such as carnitine palmitoyltransferase-1 (CPT1) [83].
Gynostemma pentaphyllum (Thunb.) Makino (GP) is a dioecious, herbaceous climbing vine
distributed in Eastern Asian. It is widely used for lowering cholesterol, and preventing fatty liver and
obesity in China and Japan. Wang et al. found that GP extracts can promote lipid metabolism, and
decrease serum lipids level by down-regulating the production of trimethylamine N-oxide (TMAO)
and up-regulating the secretion of phosphatidylcholine [84]. In a study with a NAFL cellular model,
GP extract was efficient in inhibiting the accumulation of cholesterol and triglycerides as well as
preventing oxidative stress in liver cells. Further study of the mechanisms revealed that GP enhances
the production of nitric oxide (NO) which reduces oxidative stress damage in liver cells and affects
the molecular composition of the mitochondrial phospholipid cardiolipin (CL) [85]. A randomized,
single-blind, controlled clinical trial showed that six-month dietary GP treatment can significantly
reduce the level of serum AST, ALP, insulin, and decrease the body mass index (BMI) and insulin
resistance index. In the GP group, BMI had reduced remarkably from 28.4 at month 0 to 27.5 at
month 6 (p = 0.018), total cholesterol had dropped from 228.5 (95% CI 148.06–308.94) to 206.1 (95% CI
139.35–272.85) (p = 0.004), and ALT had decreased from 80.2 (95% CI 19.53–140.87) to 63.2 (95% CI
3.99–122.51) (p = 0.004) [86]. These studies demonstrated that GP extracts can be an effective adjunct
treatment for NAFL patients. Ombuine is a flavonoid isolated from GP. Recent studies confirmed that
ombuine treatment remarkably decreased intracellular concentrations of triglyceride and cholesterol
in liver cancer cells and reduced the expression of some lipogenic genes through activating PPARα
and β/δ. Furthermore, Ombuine can also decrease cellular cholesterol concentrations by activating
ATP binding cassette cholesterol transporter A1 and G1 protein expression [87].
Panax notoginseng (Burkill) F.H.Chen (PNS) is a species of the genus Panax, which grows naturally
in China and Japan. Ding et al. found that PNS extracts can attenuate the ethanol induced hepatic
lipid accumulation by inhibiting the production of malondialdehyde (MDA), glutathione (GSH) l
and reactive oxygen species (ROS), reducing TNF-alpha and IL-6 levels, as well as enhancing the
superoxide dismutase (SOD) activity in liver, and abrogating cytochrome P450 2E1 (CYP2E1) induction.
In addition, PNS can protect liver cells from CYP2E1-mediated oxidative stress [88,89]. In vivo studies
from the same group also found that total saponins of PNS can relieve oxidative stress and insulin
resistance in NAFLD rat models. Concentrations of malondialdehyde (MDA), the hydroxy radical
level (–OH), and TNF-alpha decreased after PNS treatment, while the activities of total superoxide
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dismutase (T-SOD) and total antioxidant capacity (T-AOC) were recovered, and insulin resistance
improved significantly.
Penta-oligogalacturonide is isolated from the fruit of Crataegus pinnatifida Bunge, which is the
most often used herb in the treatment of NAFLD according to the systematic review study by
Shi et al. [90]. Recently, the anti-lipidemic and antioxidant effects of penta-oligogalacturonide were
investigated both in vitro and in vivo. The results showed that penta-oligogalacturonide was effective
in scavenging hydroxyl, superoxide anion and 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals in
liver cells. Additionally, penta-oligogalacturonide can enhance the antioxidant enzyme activities of
superoxide dismutase, catalase, and glutathione peroxidase, increase the levels of glutathione and the
total antioxidant capacity, but lower the production of malondialdehyde in the liver of high-fat fed
mice. Furthermore, penta-oligogalacturonide significantly decreased the triglyceride levels, expression
of phosphatidate phosphohydrolase (PAP) and glycerol 3-phosphate acyltransferase (GPAT) in mice
livers. Moreover, the liver biopsy results confirmed that penta-oligogalacturonide treatment at a dose
of 300 mg/kg can inhibit liver steatosis in mice with high-fat diet [91]. Another study from the same
research group also found that penta-oligogalacturonide remarkably increased the liver fatty acid
oxidation-related enzyme activities of acyl-CoA oxidase, 3-ketoacyl-CoA thiolase, 2,4-dienoyl-CoA
reductase, and carnitine palmitoyltransferase I, which may prevent hyperlipemia in the liver of high
fat diet mice [92].
Dioscin, a natural steroid saponin isolated from Dioscorea opposita Thunb, has been shown to have
a remarkable protective effect against fatty liver disease. Recent study has demonstrated that dioscin
can reduce body weight and lipid accumulation in liver, increase oxygen consumption and energy
expenditure and decrease the levels of serum ALT, AST. Further study of the mechanisms revealed
that dioscin can relieve oxidative damage, inhibit inflammation, suppress cholesterol and triglyceride
synthesis, decrease mitogen-activated protein kinase (MAPK) phosphorylation levels, promote fatty
acid beta-oxidation, and induce autophagy to improve fatty liver conditions. These results indicated
that dioscin may be a potential candidate for obesity and NAFLD prevention [93]. Dioscin also showed
an excellent protective effect against alcoholic fatty liver by relieving alcohol-induced oxidative stress,
inflammatory cytokine production, mitochondrial function, apoptosis and liver steatosis in vivo [94].
Gallic acid is a trihydroxybenzoic acid found in the pericarp of Punica granatum L. Previous
studies have confirmed that gallic acid has potent anti-oxidative and anti-obesity activity.
Chao et al. found that gallic acid can improve the glucose and lipid metastasis disorder in NAFLD mice.
The hepatoprotective effect by gallic acid may be related to regulation of the metabolism of choline,
amino acids, glucose, lipid and gut-microbiota in mice [95]. Histological study in the high fat
diet-induced NAFLD rat showed that the lipid droplets in gallic acid treatment group were significantly
smaller than the control group. When compared with the control group, cholesterol level and hepatic
triacylglycerol (TAG) in gallic acid treatment groups were remarkably reduced. Furthermore, gallic
acid treatment decreased oxidized glutathione (GSSG) content and increased the levels of anti-oxidative
enzyme in liver. These results indicated that gallic acid treatment can inhibit NAFLD-related
hepatosteatosis, dyslipidaemia and oxidative stress in rats [96].
Compound glycyrrhizin has been widely used in clinical practice for chronic liver disease.
An in vivo study has proved the therapeutic effects of compound glycyrrhizin liposome on
nonalcoholic steatohepatitis in rats in inhibiting the process of fibrosis [97]. Another study also
confirmed that the glycyrrhizin-containing preparation can suppress the development of hepatic
steatosis in a dose-dependent manner and attenuate ultrastructural alterations of mitochondria of
the hepatocytes. In addition, it can down-regulate the reactive oxygen species in mice liver [98].
These results demonstrated that the glycyrrhizin-containing preparation can prevent hepatic steatosis
possibly by preventing mitochondria damage from oxidative stress.
According to previous studies, the curative effects of silymarin in alcoholic and non-alcoholic
steatohepatitis are widely recognized [99]. Recently, siliphos, a modified derivative of silymarin,
has been proved to effectively suppress severe oxidative stress and to protect hepatic mitochondrial
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bioenergetics in nonalcoholic steatohepatitis [100]. Through protecting mitochondrial function, the
damage of lipid membranes by oxidation is alleviated by siliphos. Clinical trials also confirmed that
after siliphos treatment, ultrasonographic score for liver steatosis has decreased remarkably in patients
with nonalcoholic fatty liver disease. In addition, a significant improvement in liver enzyme levels,
indexes of liver fibrosis, and hyperinsulinemia have been observed in siliphos treatment group [101].
The kernels of Prunus armeniaca L are used as a common drug in traditional Chinese medicine. As a
popular fruit, dietary intake of Prunus armeniaca L kernels can lower cholesterol levels in the body [102].
Recent studies have found that feeding rats with the kernels of Prunus armeniaca L had protective
effects against CCl4-induced liver steatosis due to its remarkable antioxidant and radical-scavenging
capacity. The rich content of beta-carotene and vitamin may be associated with the anti-steatosis
effect by the kernels [103]. In a clinical study, the extract of Prunus armeniaca L kernels also exhibit
protective effects on fatty liver disease patients. The results showed that serum ALT and AST levels
were remarkably reduced compared with pre-intake baseline levels from 103.5 (95% CI 4.03–202.87)
IU/L to 71.8 (95% CI 5.39–138.21) IU/L (p < 0.05) and from 93.5 (95% CI 0.02–187.72) IU/L to 65.5 (95%
CI 6.69–123.31) IU/L (p < 0.05). A decrease of more than 30% from the pre-study baseline ALT and
AST levels were detected in 45% and 43% of the patients (n = 58), respectively. These results indicated
that after treating these patients with Prunus armeniaca L extracts, the serum AST and ALT levels were
significantly decreased compared with the control group [104].
Baicalin was also found to be effective in modulating lipid metabolism and suppressing systemic
inflammation in high-fat feeding rat liver and the mechanism may be related to the regulation
of AMPK-alpha signaling pathway [105,106]. Further study confirmed that baicalin can decrease
the levels of serum total cholesterol, triglycerides, low density lipoprotein (LDL), ALT and AST,
and increase the levels of serum HDL. Pathological analysis revealed a higher dose of baicalin
diminished both macrovesicular and microvesicular steatoses while a low dose of baicalin only
suppressed macrovesicular steatosis. The mechanism may be associated with the regulation of hepatic
CaMKKbeta/AMPK/ACC pathway [107]. For alcoholic fatty liver disease, baicalin is also effective in
attenuating the ischemia/reperfusion injury in alcoholic fatty liver. In ethanol-fed animals, baicalin
attenuated inflammatory responses by suppressing of myeloid differentiation factor 88 and toll-like
receptor 4 expressions and the nuclear translocation of NF-kB after reperfusion [108].
Table 2. Herbs and phytochemicals in fatty liver disease treatment.
Herbal Medicines
(Herbs or Phytochemicals)
The Sources of
Herbal
Medicines
Type of Study Biological Effects andMolecular Mechanism Reference
Berberine
Rhizoma of
Coptis chinensis
Franch
In vitro
Reducing TG accumulation
in the FFA-induced
hepatic steatosis.
[81]
In vivo
Enhancing insulin resistance
of nonalcoholic fatty liver
disease by increasing the
expression of IRS-2.
[82]
Suppressing lipogenesis and
promoting lipolysis by
inhibiting the expression of
SCD1, FAS, SREBP1c and
increasing the expression
of CPT1.
[83]
Ombuine
Whole plant of
Gynostemma
pentaphyllum
(Thunb.) Makino
In vitro
Reducing intracellular
concentrations of triglyceride
and cholesterol in HepG2
cells and decreased the
expression of several
lipogenic genes by activating
of PPARalpha and
delta/beta.
[87]
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Table 2. Cont.
Herbal Medicines
(Herbs or Phytochemicals)
The Sources of
Herbal
Medicines
Type of Study Biological Effects andMolecular Mechanism Reference
Penta-oligogalacturonide Fruit of Crataeguspinnatifida Bunge
In vitro
Scavenging hydroxyl,
superoxide anion and DPPH
radicals in liver cells.
[92]
In vivo
Enhance the antioxidant
enzyme activities of
superoxide dismutase,
catalase, glutathione
peroxidase, increase the
levels of glutathione and the
total antioxidant capacity,
but lowered the production
of malondialdehyde in the
liver of high-fat fed mice.
Glycyrrhizin
Root of
Glycyrrhiza
uralensis Fisch
In vivo
Inhibiting the process of
fibrosis on nonalcoholic
steatohepatitis in rats.
[97]
Suppressing the
development of hepatic
steatosis, attenuating
ultrastructural alterations of
mitochondria of the
hepatocyte, down-regulating
the ROS in mice liver.
[98]
Siliphos
Fruits of Silybum
marianum (L.)
Gaertn.
In vitro
Alleviating the damage of
lipid membranes by
protecting of
mitochondrial function.
[100]
Clinical study
Decreasing ultrasonographic
scores for liver steatosis in
patients with nonalcoholic
fatty liver disease.
[101]
Baicalin
Root of Scutellaria
baicalensis Georgi
In vivo
Decreasing the level of
serum total cholesterol,
triglycerides, LDL, ALT and
AST, and increase the level of
serum HDL by mediation of
CaMKKbeta/AMPK/ACC
pathway.
[107]
Clinical study
Attenuating the
ischemia/reperfusion injury
in alcoholic fatty liver by
suppressing of myeloid
differentiation factor 88 and
TLR4 protein expressions
and the nuclear translocation
of NF-kB after reperfusion.
[108]
Gallic acid
Picarp of Punica
granatum L
In vivo
Recovering impaired glucose
and lipid homeostasis in
high fat diet-induced
NAFLD mice.
[95]
In vivo
Reducing GSSG content and
oxidative stress and
increasing the levels of GSH
peroxidase, glutathione, GSH
S-transferase and GSH
reductase in liver tissue.
[96]
Dioscin
Rhizoma of
Dioscorea opposita
Thunb
In vitro and
in vivo
Relieving oxidative damage,
inhibiting inflammation,
cholesterol and triglyceride
synthesis, decreasing MAPK
phosphorylation levels,
promoting fatty acid
beta-oxidation, and inducing
autophagy to improve fatty
liver conditions.
[93]
In vivo
Protective effect against
alcoholic fatty liver by
relieving alcohol-induced
oxidative stress,
inflammatory cytokine
production, mitochondrial
function, apoptosis and
liver steatosis.
[94]
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Table 2. Cont.
Herbal Medicines
(Herbs or Phytochemicals)
The Sources of
Herbal
Medicines
Type of Study Biological Effects andMolecular Mechanism Reference
Total saponins of Panax notoginseng
(Burkill) F.H.Chen
Flower, root, leaf
of Panax
notoginseng
(Burkill) F.H.Chen
In vitro
Attenuating the ethanol
induced hepatic lipid
accumulation by inhibiting
the production of MDA,
GSH l and reactive ROS,
reducing TNF-alpha and IL-6
levels, as well as enhancing
the SOD)activity in liver,
and abrogated
CYP2E1 induction.
[88]
In vivo
Relieve oxidative stress and
insulin resistance in
NAFLD rats.
Gynostemma pentaphyllum (Thunb.)
Makino
Aqueous extract
of whole plant of
Gynostemma
pentaphyllum
(Thunb.) Makino
In vitro
Promoting lipid metabolism,
and decreasing serum lipids
level by down-regulating the
production of TMAO and
up-regulating
phosphatidylcholine.
[84]
Inhibiting the accumulation
of cholesterol and
triglycerides as well as
preventing oxidative stress
by enhancing the production
of NO and affects the
molecular composition
of the mitochondrial
phospholipid CL.
[85]
Clinical study
Reducing the level of serum
AST, ALP, insulin, decrease
BMI and insulin
resistance index.
[86]
Prunus armeniaca L
Aqueous extract
of kernels of
Prunus armeniaca
L
In vivo
Relieving CCl4-induced liver
steatosis by antioxidant and
radical-scavenging.
[103]
Clinical study
Protective effects on fatty
liver disease patient by
decreasing the serum AST
and ALT levels.
[104]
2.3. Herbs and Phytochemicals in the Treatment of Cirrhosis
2.3.1. The Epidemiological and Pathological Characteristics of Cirrhosis and Current Therapeutic Strategy
Cirrhosis is a condition in which the liver does not function properly due to long-term damage;
it is a terminal complication of chronic liver diseases. According to a study in Germany, the most
common etiologies of liver cirrhosis in German were related to alcoholic liver disease (52%), chronic
Hepatitis C (28%) or Hepatitis B (14%) infection and NASH (6%) [109]. However, the situation in
developing countries is quite different; for example, in China, the distribution of etiological agents for
cirrhosis was as follows: HBV 77.22%, alcohol 5.68%, HCV 2.80%, and the other etiologies accounted
for about 15% [110]. Cirrhosis-related deaths increased from about 676,000 cases in 1980, or 1.54% of
total global deaths, to more than 1,000,000 deaths in 2010, or 1.95% of the global deaths [111].
The pathological hallmark of cirrhosis is the development of fibrosis that replaces normal
parenchyma. Fibrosis means overabound scar tissue builds up in the liver during wound healing and
damage repair. The extracellular matrix (ECM) proteins such as collagens are excessively produced
or deficiently degraded in this process, which may be due to the chronic inflammation or fatty liver.
Fibrosis is potentially reversible if the cause is removed at this stage, but advanced fibrosis may further
develop to cirrhosis which involves loss of hepatic cells and irreversible scarring in liver. Recent
studies show the pivotal role of the stellate cells in the development of cirrhosis. Inflammation in the
liver parenchyma can cause activation of hepatic stellate cells, which further leads to fibrosis formation
and blood circulation obstruction. In addition, it secretes cytokines such as TGF-β1, which further
promotes the fibrotic response and proliferation of connective tissue. Furthermore, it secretes tissue
inhibitor of metalloproteinases (TIMPs) which inhibit the activity of matrix metalloproteinases (MMPs)
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and suppress them from resolving fibrotic material in the ECM [112]. Several mitogen-activated
protein kinases regulate major fibrogenic actions of stellate cells. For example, c-Jun N-terminal kinase
regulates apoptosis of hepatic cells and induces the secretion of inflammatory cytokines by stellate
cell [113]. The focal adhesion kinase PI3K-Akt–signaling pathway regulates agonist-induced fibrogenic
actions in stellate cell [114]. The TGF-β1–activated Smad-signaling pathway modulates experimental
hepatic fibrosis in vitro and is a potential target for anti-fibrosis [115]. The PPAR pathway modulates
stellate cell activation and fibrosis process. PPAR-γ ligands suppress the fibrogenic process in stellate
cell in vitro and in vivo [116]. Recent studies suggest that NF-κB, Toll-like receptors and β-cathepsin
may be involved in fibrosis regulation [117,118].
So far, there is no treatment that can radically reverse cirrhosis except for liver transplantation,
but the supply of liver allografts is far short of the number of potential recipients [119]. Key prevention
strategies for current cirrhosis management are through further prevention of liver damage by hepatitis
or fatty liver disease. Unlike the irreversible process of cirrhosis, recent researches have proved that
even advanced fibrosis is remediable. The appropriate anti-fibrosis therapy should target the reduction
of lavish collagen deposition specifically without destroying normal ECM. Although no drugs have
been approved for treating fibrosis or cirrhosis in USA, some herbal medicines have shown remarkable
efficiency in preventing cirrhosis and treating fibrosis or relieving symptoms of cirrhosis (Table 3).
2.3.2. Herbs and Phytochemicals in the Treatment of Cirrhosis
The hepatoprotective effect by CRAE on CCl4-induced chronic liver hepatotoxicity such as fibrosis
has been reported by many studies [120,121]. These results showed that serum ALT and AST activities
were remarkably decreased in CCl4-induced rats when treated with CRAE. The significant increase of
serum SOD activity and the histological results proved that CRAE could recover CCl4-induced chronic
oxidative stress by anti-oxidant mechanisms. In addition, another study found that the myofibroblast
proliferation and the expression of TGF-b1 and a-SMA were remarkably decreased after berberine
treatment [122]. These studies proved that CRAE and berberine could be promising anti-fibrosis agents
in preventing and treating liver disease. The further mechanism study showed that the anti-fibrosis
effects by berberine may be induced by activation of AMPK, blockade of Nox4 and Akt expression [123].
A comparative research on the hepatoprotective action of bear bile and CRAE on experimental liver
fibrosis in rats demonstrated that berberine, CRAE, and bear bile all exhibited anti-fibrotic properties
on liver fibrosis [124]. All of these agents could remarkably increase the SOD activity and reduce the
peroxidative stress in rat liver. CRAE and berberine can protect hepatocytes from cholestatic damage
through excreting bilirubin products from the liver. These results illustrated that CRAE and berberine
may be promising agents to replace the valuable bear bile for liver fibrosis in clinical practice.
Puerarin is a kind of isoflavones isolated from Pueraria lobata. Recent studies have found
that puerarin could promote the liver metabolic function and reduce the levels of ALT, AST and
total-bilirubin, ECM contents and up-regulate the levels of albumin and total-protein in liver fibrosis
rats. Further studies showed that puerarin could relieve the CCl4-induced liver fibrosis in vivo; the
mechanisms may be related with modulation of the expression of PPAR-γ protein and PI3K/Akt
pathway [125]. Another study found the TNF-alpha/NF-kB pathway was also involved in puerarin
mediated anti-fibrosis effects in hepatic fibrotic rats. Through down-regulating the TNF-alpha and
NF-kB expression by puerarin treatment, the inflammation response in liver tissue was relieved and
the metabolic function was also improved [126]. Puerarin can also induce apoptosis of hepatic stellate
cells, which plays a pivotal role in liver fibrosis. Further study of the mechanisms confirmed that
down-regulation of bcl-2 mRNA are involved in puerarin induced hepatic stellate cells apoptosis [127].
Saururus chinensis (Lour.) Baill has been used in Chinese medicine for treating jaundice, gonorrhea
and edema as well as reversing liver fibrosis [128,129]. Saururus chinensis (Lour.) Baill extract can
effectively reduce the elevated levels of liver indexes such as serum ALT, AST, hyaluronic acid (HA),
and hepatic MDA contents in hepatic fibrotic rats, it can also enhance the hepatic SOD activity after
CCl4-treatment. The histopathological results proved that Saururus chinensis (Lour.) Baill extract
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significantly relieved the CCl4-induced liver fibrosis. These results demonstrated the hepatoprotective
effect of Saururus chinensis (Lour.) Baill extract on CCl4-induced liver fibrosis [130].
The protective effect of glycyrrhizin on liver cirrhosis has been proved by both in vitro and in vivo
studies. The mechanism of the anti-cirrhosis effect of glycyrrhizin perhaps has an inhibitory effect
on NF-kB binding activity [131]. In this research, both the serum ALT detection and histological
analysis results proved the anti-cirrhosis effect by glycyrrhizin. In addition, NF-kB binding activity
was significantly decreased after glycyrrhizin treatment in the liver specimens of cirrhosis rats.
18alpha-glycyrrhizin, a modified derivative of glycyrrhizin, also showed obvious anti-fibrosis effects
in CCl4-induced liver damage in rats. 18alpha-glycyrrhizin treatment improved histological changes
and inhibited collagen deposition by decreasing the expressions of Smad2, Smad3, SP-1 and TGF-beta1
in both mRNA and protein level in the liver [132]. A phase III clinical study also confirmed the
anti-fibrosis efficacy and safety of glycyrrhizin in 379 chronic Hepatitis C patients who failed to respond
to interferon-based treatment. Results showed that 12-week treatment with 5ˆ/week glycyrrhizin
injections could decrease ALT level ě50% in 28.7% patients and in the effect of 3ˆ/week glycyrrhizin
injections group the proportion was 29.0%, which were much more significant than placebo group
(7.0%, p < 0.0001). Fifty-two week treatment can relieve the necro-inflammation in liver in 44.9%
patients with 5ˆ/week and in 46.0% patients with 3ˆ/week, respectively. These results indicated that
glycyrrhizin can reduce serum ALT level after 12 weeks of treatment and suppress necro-inflammation
and fibrosis after 52 weeks of treatment compared to placebo group. In addition, no obvious side-effect
by glycyrrhizin was detected in the clinical trial [133].
Silybinin, which is also known as silybin, exhibits antioxidant effect and induces mitochondrial
biogenesis in cirrhotic livers [134]. Silybinin can prevent the production of mitochondrial reactive
oxygen species (ROS) and inhibit the cardiolipin oxidation or citrate carrier failure in the liver of
cirrhosis rat model. Silybinin also exhibits significant anti-inflammatory effect in cirrhotic rat liver
by decreasing the expression of lysophosphatidylcholine acyltransferase (LPCAT) while increasing
platelet-activating factor level [135]. A clinical survey indicated that silymarin can reduce symptoms
and quality-of-life in cirrhosis patients. Long-term use of silymarin may provide benefits to patients
with chronic Hepatitis C [136]. However, the effects of silymarin on survival rate or the disease
progression of liver cirrhosis remains controversial in clinical practice [137].
Bupleurum kaoi Liu, C.Y.Chao & Chuang, a plant of endemic Bupleurum species in Taiwan, exhibits
anti-fibrotic and anti-inflammatory activities in liver cells. These effects are proved to be associated
with the anti-oxidant activity by observing the increased glutathione expression. It can also regulate the
liver cell regeneration through the increased expression of IL-10 and INF-gamma. In addition, when
compared with the Bupleurum chinense DC, the anti-fibrotic and hepatoprotective effects of Bupleurum
kaoi are more significant [138]. Saikosaponin A, the major active ingredients in Bupleurum chinense
DC, was found to increase the expression of bone morphogenetic protein 4 (BMP-4) and inhibit the
activation of hepatic stellate cells [139]. When combining IFN-alpha treatment with saikosaponin,
it could significantly reduce the damage of immune hepatic injury. In this study, the combination
therapy can increase peripheral blood CD4+ T cell and CD8+ T cell ratios more significantly than
using IFN-alpha alone. Meanwhile, the IL-18 and TNF-alpha levels both decreased obviously in
combination therapy [140]. A recent study has indicated that saikosaponin A can be used for treatment
of BMP-4 induced liver damage. Their result showed that the development of liver fibrosis was
remised in the saikosaponin treatment group. The saikosaponin treatment can down-regulate plasma
aspartate aminotransferase and alanine aminotransferase activities. In addition, the plasma and hepatic
cholesterol and triglyceride levels also decreased after saikosaponin treatment [141].
The isolated Salvianolic acid B from Salvia miltiorrhiza Bunge has anti-fibrosis effect in liver
diseases. Salvianolic acid B can inhibit intracellular signal transduction of TGF-β1 in hepatic stellate
cells and suppress the expression of its receptor protein, thereby antagonizing the hepatic stellate
cells activation, and inhibiting the fat-storing cell proliferation as well as reducing the deposition
of collagen fiber in liver. A related animal study also confirmed that the Salvia miltiorrhiza Bunge
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treated liver tissues exhibited little fibrous tissue deposition in the portal areas, presented normal tissue
morphology, and obviously decreased collagen deposition. In addition, decreased tissue inhibitor of
metalloproteinase (TIMP)1 and collagen 1(alpha) protein also supports the anti-fibrotic effect of Salvia
miltiorrhiza Bunge [142]. In animal studies, Salvia miltiorrhiza Bunge extracts have appeared to inhibit
the process of liver fibrosis and improve liver function by reducing the nonfunctioning fibers in the
liver. For people who have chronic hepatitis or excessive consumption of alcohol, Salvia miltiorrhiza
Bunge is recommended for protecting their liver function [143].
The increase of glutathione S-transferase A5 expression and decrease of P450 cytochrome 3A2 by
Scutellaria baicalensis Georgi extracts was also observed in liver cells. Treatment with methanolicextracts
of Scutellaria baicalensis Georgi significantly reduced the levels of liver malondialdehyde and
hydroxyproline with ameliorative histological results, which indicated the anti-fibrosis effect of
Scutellaria baicalensis Georgi [144]. Scutellaria baicalensis Georgi extract also suppresses the proliferation
and activation of hepatic stellate cells by inducing cell cycle arrest in G2/M phase and stellate
cell apoptosis via caspases and Bax pathway [145]. Baicalein may be the main active component
in Scutellaria baicalensis Georgi for prevention of cirrhosis and fibrosis. In vivo studies confirmed
that baicalein can inhibit hypertrophic scar formation by suppressing TGF-beta/Smad2/3 signaling
pathway in mice with mechanical load-induced scars [146]. Long-term administration of baicalein
may suppress stellate cell activation by decreasing the expression of PDGF-beta receptor, and thus it
can restrain the development process of liver fibrosis in animal models [147].
Table 3. Herbs and phytochemicals in cirrhosis treatment.
Herbal Medicines
(Herbs or
Phytochemicals)
The Sources of
Herbal Medicines Type of Study
Biological Effects and Molecular
Mechanism Reference
Berberine Rhizoma of Coptischinensis Franch In vivo
Remedying CCl(4)-induced chronic
oxide stress by anti-oxidant
mechanisms, reducing
myofibroblast proliferation and the
expression of TGF- b1 and a-SMA.
[122]
Puerarin Rhizoma of Puerarialobata In vivo
Attenuating the CCl4-induced
toxicity in the hepatic cells of
hepatic fibrosis rats, mediating
anti-fibrosis effects through
modulating the PPAR-gamma
expression and inhibiting the
PI3K/Akt signal pathway.
[125]
Mediating anti-fibrosis effects in
hepatic fibrosis rats through
down-regulating the TNF-alpha and
NF-kB expression.
[126]
Inducing apoptosis of hepatic
stellate cells by down-regulating
bcl-2 mRNA.
[127]
Glycyrrhizin Root of Glycyrrhiza
uralensis Fisch
In vivo
Reducing serum ALT and
improving histological changes by
decreasing NF-kappa B
binding activity.
[131]
Improving histological changes and
inhibited collagen deposition by
decreasing the expressions of
Smad2, Smad3, SP-1 and TGF-beta1.
[132]
Clinical study
Reducing serum ALT level after 12
weeks of treatment and suppression
of necro-inflammation and fibrosis.
[133]
Silybinin Fruits of Silybum
marianum (L.) Gaertn. In vivo
Preventing the production of
mitochondrial ROS and inhibiting
the cardiolipin oxidation or citrate
carrier failure in the liver of
cirrhosis rat.
[134]
Exhibiting significant
anti-inflammatory effects in
cirrhotic rat liver by decreasing the
expression of LPCAT and increasing
platelet-activating factor level.
[135]
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Table 3. Cont.
Herbal Medicines
(Herbs or
Phytochemicals)
The Sources of
Herbal Medicines Type of Study
Biological Effects and Molecular
Mechanism Reference
Saikosaponin A
Root of Bupleurum kaoi
Liu, C.Y.Chao &
Chuang
In vitro
Increasing the expression of BMP-4
and inhibiting the activation of
hepatic stellate cells.
[139]
In vivo
Combination therapy with
IFN-alpha can increase peripheral
blood CD4+ T cells and CD8+ T cell
ratios, down-regulating plasma AST
and ALT activities, decreasing the
plasma and hepatic cholesterol and
triglyceride levels.
[140,141]
Salvianolic acid B
Root and rhizome of
Salvia miltiorrhiza
Bunge
In vitro
Inhibiting intracellular signal
transduction of TGF-β1 in hepatic
stellate cells and suppressing the
expression of its receptor protein.
[142]
In vivo
Decreasing fibrous tissue deposition
in the portal areas, and obviously
decreasing collagen deposition. In
addition, decreasing oTIMP1 and
collagen 1(alpha) protein.
Inhibiting the process of liver
fibrosis and improve liver function
by reducing the nonfunctioning
fibers in the liver.
[143]
Baicalein
Root of Scutellaria
baicalensis Georgi In vivo
Inhibiting hypertrophic scar
formation by suppressing
TGF-beta/Smad2/3 signaling
pathway in mice with mechanical
load-induced scars.
[146]
Suppressing stellate cell activation
by decreasing the expression of
PDGF-beta receptor.
[147]
Silymarin
Flavonolignans
mixture from the
fruits of Silybum
marianum (L.) Gaertn.
Clinical study
Long-term use may reduce
symptoms and quality-of-life in
cirrhosis patients.
[137]
Coptis chinensis Franch
Aqueous extract of
rhizoma of Coptis
chinensis Franch
In vivo
Increasing serum SOD activity and
the histological results in
CCl(4)-induced liver fibrosis by
anti-oxidant mechanisms.
[120,121]
Saururus chinensis
(Lour.) Baill
Ethanol extract of
rhizoma of Saururus
chinensis (Lour.) Baill
In vivo
Reducing the elevated levels of liver
index such as serum ALT, AST, HA,
and hepatic MDA contents in
hepatic fibrosis rats.
[130]
Bupleurum kaoi Liu,
C.Y.Chao & Chuang
Ethanol extract of root
of Bupleurum kaoi Liu,
C.Y.Chao & Chuang
In vitro
Exhibiting the anti-fibrotic and
anti-inflammatory activities in liver
cells by anti-oxidant activity of
increasing glutathione expression.
[138]
Scutellaria baicalensis
Georgi
Ethanol extract of root
of Scutellaria
baicalensis Georgi
In vitro
Reducing the levels of liver
malondialdehyde and
hydroxyproline significantly, with
ameliorative histological results
which indicated
the anti-fibrosis effect.
[144]
Suppressing the proliferation and
activation of hepatic stellate cells by
inducing cell cycle arrest in G2/M
phase and inducing stellate cell
apoptosis via caspase and
Bax pathway.
[145]
2.4. Herbs and Phytochemicals in the Treatment of Primary Liver Cancer
2.4.1. The Epidemiological and Pathological Characteristics of Primary Liver Cancer and Current
Therapeutic Strategy
The incidence of primary liver cancer is increasing in many industrialized countries, it is the sixth
most frequent diagnosed cancer globally, and has become the second leading cause of cancer death
since 2014. In 2010, primary liver cancer become the third leading cause of cancer death worldwide,
with 754,000 deaths related with this disease. In 2012, about 782,000 people were diagnosed with
primary liver cancer and 746,000 people eventually died from this disease. The occurrence of liver
cancer may be associated with hepatitis virus infection (71%) and alcoholic abuse (20%). In 2014,
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liver cancer resulted in more than 750,000 deaths globally [148].The incidence of liver cancer is higher
in those countries where hepatitis virus infection are common, such as East-Asia and sub-Saharan
Africa [149]. The five year survival rate of primary liver cancer is only 17% in the United States in 2014
and even lower in developing countries [150]. Hepatocellular carcinoma (HCC) is the most common
type of primary liver cancer, which shows an obvious geographical distribution. For example, 50% of
HCC are diagnosed in China [151].
The leading cause of liver cancer is cirrhosis induced by viral hepatitis or fatty liver disease.
Hepatitis or fatty liver promote the development of HCC through repeatedly inducing the immune
system to attack the hepatic cells, while this constant cycle of damage followed by repair can lead to
mistakes during repair which in turn lead to carcinogenesis. For chronic Hepatitis B, the integration
of the viral genome into the host liver cells can directly induce gene mutation and thereby develop
HCC. The disorders in Wnt, TGF-β, Hedgehog and Notch signaling pathways play a pivotal role in
the oncogenesis process of HCC. Some other factors such as microRNAs may also regulate the liver
oncogenesis process [152,153].
So far, the treatment for liver cancer is limited, the later stage or higher-grade liver cancer patients
will ordinarily have poor prognosis [154]. Surgical resection may be the best therapy for promoting
long-term survival, but because most patients are diagnosed at the later stage of disease, therefore only
10% of the patients are suitable for surgical resection. Sorafenib, a receptor tyrosine kinase inhibitor
which has been approved in the US and Europe, may be beneficial for patients with advanced HCC.
Unfortunately, Sorafenib increases lifespan by only two months for late stage HCC patients with
satisfactory liver function according to a phase III clinical trial [155]. Under these circumstances, herbal
medicines are recommended as an alternative treatment for liver cancer patients, in order to reduce
the side-effects from conventional therapy and prolong survival time as well as improve life quality
(Table 4).
2.4.2. Herbs and Phytochemicals in the Treatment of Primary Liver Cancer
The recent pharmacological studies have demonstrated that both Coptidis rhizoma and berberine
have a prominent hepatoprotective effect, especially the anti-cancer effect on hepatocellular carcinoma.
A recent research has shown that the alkaloids in Coptidis rhizoma aqueous extract (CRAE) inhibited
vascular endothelial growth factor (VEGF) by suppressing the activity of eukaryotic elongation
factor 2 (eEF2) in liver cancer [156]. The phytochemical study showed that the major alkaloids
in CRAE are berberine, jatrorrhizine, magnoflorine and palmatine. These alkaloids could suppress
VEGF secretion in HepG2 and MHCC97L cells while no significant toxicity has been observed in
normal liver cells. This inhibition effect was mainly observed for protein level rather than mRNA
transcriptional level. The alkaloids in CRAE also inhibited the activation of eEF2 by raising the
phosphorylation levels of eEF2 and thereby blocked the nascent protein synthesis. Berberine was
found to be the main active ingredient in these alkaloids but the total alkaloids in CRAE is more
effective in inhibiting the activity of eEF2. The in vivo study also confirmed that the tumor size of
xenograft mice was significantly reduced after Coptidis rhizoma treatment. According to another study
by our research group, miR-23a expression can be upregulated by berberine treatment in human HCC
cells and may activate the transcription of p53-related tumor suppressive GADD45alpha and p21
genes. In vivo study also showed that when miR-23a expression was inhibited, the berberine-induced
tumor suppression in mice was attenuated [157]. Another study also confirmed that CRAE suppressed
HCC growth by targeting on miR-21 and miR-23a [158]. The invasion-chamber and wound-healing
experiments showed that CRAE could suppress HCC migration through inhibition of Rho/ROCK
signaling pathway and the total alkaloids in CRAE may be promising agents for preventing cancer
invasion [159]. On the other hand, we also found that berberine could induce HCC cell death via
apoptosis and autophagy. The mechanisms may be related with activation of Beclin-1 to induce
mitochondrial apoptosis and suppression of mTOR to induce autophagic cell death in HCC by
berberine [160].
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As complementary herbal medicine, long term administration of silymarin can inhibit cell
proliferation, induce cell apoptosis, and sensitize the detoxification system in HCC cells [161].
The chemopreventive effect of silymarin on HCC has been demonstrated in both in vitro and in vivo
studies [162]. It can interfere with cytokines’ expression and regulate cell survival and apoptosis.
Moreover, silymarin can inhibit inflammation and metastasis of HCC. The potential molecular
mechanisms are associated with reduced mitochondrial transmembrane potential of liver cells followed
by increased expression of cytosolic cytochrome c and pro-apoptotic proteins such as Bax, p53,
caspase-3 and APAF-1 and down-regulation of anti-apoptotic proteins (survivin and Bcl-2) and
proliferation-related proteins (beta-catenin, c-Myc, PCNA, and cyclin D1) [163]. All these further
suggested that silymarin could be a promising adjuvant agent for HCC treatment.
When combining Bupleurum chinense DC with chemotherapy, increased micronuclei frequency and
DNA damage have been observed on liver cancer cells [164]. When saikosaponin D was used to treat
HepG2 cells, a significant increase of cell apoptosis was observed. The mechanisms of apoptosis may
associate with the activation of caspases 3 and 7 and finally cause DNA fragmentation. Saikosaponin
D also sensitizes radiotherapy on hepatoma cells under hypoxic conditions by suppressing HIF-1
alpha expression [165]. In vivo studies found that saikosaponin D can inhibit HCC development and
metastasis by decreasing the expression of syndecan-2, MMP-2, MMP-13 in rat liver cells [166].
Rui et al. found that Salvia miltiorrhiza Bunge extracts prevents human HCC on DEN-induced
hepatocarcinogenesis by suppressing fibrosis and plasminogen activator inhibitor-1 mRNA
transcription in a dose-dependent manner [167]. Further studies found that tanshinones may be
the major anti-cancer ingredient in Salvia miltiorrhiza Bunge with the observation in in vitro studies
that significant cytotoxic effects were incurred by tanshinones on doxorubicin-resistant human HCC
cells. The cryptotanshinone suppressed doxorubicin efflux, a process mediated by P-glycoprotein,
in Pgp-overexpressed drug resistance HepG2 cells. The tanshinone IIA, another kind of tanshinone,
exhibits pro-apoptotic effects and better synergism with doxorubicin in HCC cells [168]. Another
study also confirmed the cytotoxicity of tanshinone IIA in HCC cells. Tanshinone IIA can induce cell
apoptosis without influencing oxidative stress in vitro. However, other tanshinones in the study have
not shown significant effect in inducing apoptosis in HCC cells [169].
The anti-cancer and anti-metastatic effect of wogonin have been reported in many studies.
The actions of wogonin may be attributed to suppression of VEGF C-induced lymphangiogenesis
as postulated by the decrease in VEGF-C-induced VEGFR-3 phosphorylation through suppression
of IL-1beta and COX-2 [170]. Pretreatment with wogonin also obviously down-regulated hepatic
DNA adducts’ formation in mice which indicated that wogonin might have protective effects against
genotoxicities [171]. Although the anti-cancer effects of wogonin has been proved in many in vitro
studies, the in vivo application of wogonin is limited due to its poor solubility and lack of specificity.
Study on the anti-HCC effect by wogonin showed that modified wogonin liposomes can improve the
bio-distribution, accumulation of the drug at the tumor tissue and enhance the therapeutic efficacy on
liver cancer [172].
Elemenes are a group of closely related natural compounds found in Curcuma aromatica Salisb.
Recent study found that beta-elemene can induce cell apoptosis and suppress the proliferation of
HepG2 cells, and the mechanism may be related to the suppression of microtubular polymerization
and decrease of alpha-tubulin [173]. Bao et al. found that beta-elemene can suppress the growth of H22
ascites hepatoma cells in a dose-and time-dependent manner. According to the study, beta-elemene
can suppress the growth of H22 cells through increasing the expression of histone H1 protein. These
findings indicated that beta-elemene may be a potential antitumor agent for liver cancer treatment [174].
Brucea javanica (L.) Merr extracts have been found to have low toxicity but potent anti-cancer
effect in many studies. Recent studies have found that Brucea javanica (L.) Merr extracts can
induce liver cancer cell apoptosis by regulating mitochondrial dependent pathway and activating
caspase 3 [175]. Yue et al. demonstrated that Brucea javanica (L.) Merr extracts can significantly suppress
the proliferation of HepG2 cells in a dose-dependent manner. Compared with the control group, the
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in vivo treatment group of Brucea javanica (L.) Merr extracts had lower metastasis rate and higher body
weight. The Brucea javanica (L.) Merr extracts induce apoptosis in hepatocellular carcinoma tissue in a
dose-dependent manner [176].
Camptothecin, a cytotoxic quinoline alkaloid, is widely used as DNA enzyme topoisomerase I
inhibitor in cancer treatment. It was isolated from the bark or stem of Camptotheca acuminata Decne, a
tree distributed in China and has been used as an anti-cancer herb in traditional Chinese medicine.
Li et al. found that camptothecin can suppress SMMC-7721 cell growth by arresting cell cycle
at the S and G2/M phases, and induce mitochondrial pathway mediated apoptosis in vitro [177].
Camptothecin can also induce TRAIL-mediated apoptosis in HCC cells by increasing ROS and
ERK/p38-dependent DR5. Further studies confirmed that pretreatment of HCC cells with antioxidants
or DR5 specific inhibitors of p38 and ERK can decrease camptothecin-TRAIL-induced cell apoptosis
by inhibiting DR5 expression [178]. In vivo studies proved that the encapsulated camptothecin with
N-trimethyl chitosan (CPT-TMC) may have high solubility and better efficacy for liver cancer treatment.
In hepatic carcinoma bearing BALB/c mice model, CPT-TMC significantly suppressed tumor growth
and lymphatic metastasis as well as extended survival time, while no obvious side-effect is observed.
Thus, CPT-TMC may be a potential safe and effective therapeutic agent for liver cancer treatment [179].
Curcumin is a diarylheptanoid isolated from turmeric which belongs to the ginger family. It is
originally used as food additive in food coloring, and it has also been investigated in many studies
for its remarkable in vitro and in vivo anticancer effects. Notarbartolo et al. found that when curcumin
used alone or in combination with doxorubicin or cisplatin can inhibit cell proliferation and induce
apoptosis in human liver carcinoma cells. The researchers further explored the changes in IAP gene
expression and NF-kB activation levels after curcumin treatment. However, there are no significant
changes in NF-kB activation, which indicated the anti-cancer effects by curcumin may be related
to other mechanisms [180]. For curcumin-resistant liver cancer cells, a recent study has revealed
that Chk1-mediated G2/M cell cycle arrest may be related with curcumin resistance and Chk1 may
be a potential target for future study in reversing resistance and improving the clinical efficacy of
curcumin [181].
Table 4. Herbs and phytochemtableicals in primary liver cancer treatment.
Herbal Medicines
(Herbs or
Phytochemicals)
The Sources of
Herbal Medicines
Type of Study
Biological Effects and Molecular
Mechanism
Reference
Berberine
Rhizoma of Coptis
chinensis Franch
In vitro and
in vivo
Increasing miR-23a expression in
human HCC cells and may activate
the transcription of p53-related tumor
suppressive GADD45alpha and
p21 genes.
[158]
In vitro
Inducing mitochondrial apoptosis in
liver cancer cells and activating
autophagic cell death in liver cancer
cells by activation of Beclin-1 and
suppressing the
mTOR-signaling pathway.
[160]
Saikosaponin D
Root or leaf of
Bupleurum chinense
DC
In vitro
Increasing cell apoptosis by activation
of caspases 3 and 7 and finally causing
the DNA fragmentation.
[165]
In vitro
Inhibiting HCC development and
metastasis by decreasing the
expression of syndecan-2, MMP-2,
MMP-13 in rat liver cell.
[166]
Cryptotanshinone,
Tanshinone IIA
Root and rhizome
of Salvia miltiorrhiza
Bunge
In vitro
Suppressing doxorubicin efflux by
regulating P-glycoprotein expression.
[168]
In vitro
Inducing apoptotic effects without
influencing oxidative stress and
synergism with doxorubicin in
HCC cells.
[168]
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Table 4. Cont.
Herbal Medicines
(Herbs or
Phytochemicals)
The Sources of
Herbal Medicines
Type of Study
Biological Effects and Molecular
Mechanism
Reference
Wogonin
Root of Scutellaria
baicalensis Georgi
In vitro
Suppressing the VEGF-C-induced
lymphangiogenesis by a decrease in
VEGF-C-induced VEGFR-3
phosphorylation through suppressing
of IL-1beta and COX-2 production.
[170]
In vivo
Exhibiting protective effects against
genotoxicities by down-regulating
hepatic DNA adducts’ formation
in mice.
[171]
Beta-elemene
Rhizome of
Curcuma aromatica
Salisb
In vitro
Inducing cell apoptosis and
suppressing the proliferation of
HepG2 cells by suppressing
microtubular polymerization and
decreasing alpha-tubulin.
[173]
In vitro
Suppressing the growth of H22 cells
by increasing the expression of histone
H1 at the protein level.
[174]
Camptothecin
Bark or stem of
Camptotheca
acuminata Decne
In vitro
Suppressing SMMC-7721 cell growth
by arresting cell cycle at the S and
G2/M phases, and inducing
mitochondrial pathway
mediated apoptosis.
[177]
In vitro
Inducing TRAIL-mediated apoptosis
in HCC cells by increasing ROS and
ERK/p38-dependent DR5.
[178]
Curcumin
Rhizome of
Curcuma longa L
In vitro
Inhibiting cell proliferation and
inducing apoptosis on human liver
carcinoma cells.
[180]
Silymarin
Flavonolignans
mixture from the
fruits of Silybum
marianum (L.)
Gaertn.
In vivo
Inhibiting cell proliferation, inducing
cell apoptosis, and sensitizing the
detoxification system in hepatocellular
carcinoma cells.
[161]
In vitro and
in vivo
Inhibiting inflammatory activity and
metastases of HCC cells by
down-regulating the mitochondrial
transmembrane potential of liver cells.
[163]
Coptidis rhizoma
Aqueous extract of
rhizoma of Coptis
chinensis Franch
In vitro and
in vivo
Inhibiting VEGF by suppressing the
activity of eEF2 in liver cancer
[156]
In vitro
Suppressing HCC cells migration
through Rho/ROCK signaling
pathway inhibition.
[159]
Bupleurum chinense DC
Aqueous extract of
root or leaf of
Bupleurum chinense
DC
In vitro
Increasing the micronuclei frequency
and DNA damage in liver cancer cells
in combination with chemotherapy.
[164]
Salvia miltiorrhiza Bunge
Aqueous extract of
root and rhizome of
Salvia miltiorrhiza
Bunge
In vivo
Preventing human HCC on
DEN-induced hepatocarcinogenesis
by suppressing fibrosis and
plasminogen activator inhibitor-1
mRNA transcription.
[167]
Brucea javanica (L.) Merr
Aqueous extract of
seeds of Brucea
javanica (L.) Merr
In vitro
Inducing liver cancer cell apoptosis by
regulating the mitochondrial
dependent pathway and
activating caspase 3.
[175]
In vitro and
in vivo
Suppressing the proliferation of
HepG2 cells in a dose-dependent
manner and inhibiting metastasis.
[176]
3. Traditional Chinese Medicine Herbal Formulae for Chronic Liver Disease Treatment
With the rapid development of Omicsresearch such as genomics, proteomics and metabolomics,
the study of the essence of traditional Chinese medicine (TCM) herbal formulas in clinical therapy
has received more attention worldwide [182,183]. Different from Western medicine which focuses
on specific pathogenic processes, TCM emphasizes the importance of individualized therapy based
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on syndrome differentiation. The TCM herbal formulas which consist of several herbs, mineral or
animal organs have been applied in treating liver diseases for thousands of years in China and some
Asian countries (Figure 1). Although some studies including clinical trials have proved that TCM
herbal formula have multiple targets in treating liver disease [184–186], the related mechanisms of the
hepatoprotective effects of these herbal formulas are still not fully understood.Int. J. Mol. Sci. 2015, 16, page–page 
25 
 
Figure 1. The traditional Chinese medicine (TCM) herbal formulas for chronic liver disease treatment. 
FZHY = Fuzheng Huayu tablet; XCHT = Xiao Chai Hu Tang; HLJD = Huanglian Jiedu decoction;  
BJRG = Biejia ruangan tablet. 
3.1. Fuzheng Huayu Tablet for Chronic Liver Disease Treatment 
Fuzheng Huayu (FZHY) tablet was the first TCM formula which completed a US Food and Drug 
Administration (FDA) phase II clinical trial for liver disease treatment. The FZHY formula consists 
of six types of traditional Chinese medicines: Semen persicae, Fructus Schisandrae chinensis, Radix 
Fermentation Mycelium Powder, Salvia miltiorrhiza Bungee, Gynostemma pentaphyllammak and Pollen  
Pini [187]. According to a double-blinded, placebo-controlled, multi-center clinical phase II trial, 
FZHY tablet could be an effective and safe treatment for liver fibrosis in chronic Hepatitis C patients. 
The efficacy of FZHY treatment was confirmed by statistical analysis using Bayes classification model. 
After FZHY treatment, the levels of both hyaluronic acid and TCM syndrome score were significantly 
decreased (p < 0.05) compared to placebo group [188]. A recent study showed that the FZHY formula 
prevents fibrosis and nourishes steatohepatitis by regulating the oxidative stress related genes and 
the IKKbeta/NF-kB, and TGF-beta1/Smad signaling pathways in mice model [189]. For HBV related 
liver damage, FZHY recipe also showed good therapeutic effects in down-regulating the levels of 
AST, ALT as well as HBV DNA concentration. A recent clinical trial study also showed that FZHY 
capsule significantly decreases the ratio of TGF-beta1/BMP-7 mRNA in chronic viral Hepatitis B 
related fibrosis patients. FZHY could significantly decrease the ratio of TGF-beta1/BMP-7 (0.09 vs. 
0.25, p < 0.05). In terms of pathological changes of the liver, the inflammatory activity for G3 and 
fibrosis degree S3 in the FZHY group was significantly lower than that in the control group (p < 0.05). 
In addition, the drug resistance related HBV YMDD variation in control group was higher than in 
the FZHY group [190]. In a multicenter clinical study, FZHY capsule showed satisfactory effects in 
treating chronic Hepatitis B related liver fibrosis with fewer adverse effects. Compared to another 
traditional hepatoprotective formula, the Heluoshugan capsule, the FZHY capsule had a better effect 
in suppressing inflammatory activity [191]. The FZHY tablet could inhibit the autocrine activation 
pathway of hepatic stellate cells. This effect may be associated with the suppression of VEGF in 
hepatic stellate cells [192]. As one of the patented TCM formulas, the phase III studies of FZHY tablet 
has just started in the US in 2014, which will give more information on the safety and efficacy of the 
FZHY tablet in different populations in the future. 
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3.1. Fuzheng Huayu Tablet for Chronic Liver Disease Treatment
Fuzheng Huayu (FZHY) tablet was the first TCM formula which completed a US Food and
Drug Administration (FDA) phase II clinical trial for liver disease treatment. The FZHY formula
cons sts of six types of traditio al Chinese med cines: Semen persicae, Fructus Schisandrae chinensis,
Radix Fermentation Mycelium Powder, Salvia miltiorrhiza Bungee, Gynostemma pentaphyllammak and
Pollen Pini [187]. According to a double-blinded, placebo-controlled, multi-center clinical phase II
trial, FZHY tablet could be an effective and safe treatment for liver fibrosis in chronic Hepatitis C
patients. The efficacy of FZHY treatment was confirmed by statistical analysis using Bayes classification
model. After FZHY treatment, the levels of both hyaluronic acid and TCM syndrome score were
significantly dec ased (p < 0.05) mpared to placebo group [188]. A recent stud showed that the
FZHY formula prevents fibrosis and nourishes steatohepatitis by regulating the oxidative stress related
genes and the IKKbeta/NF-kB, and TGF-beta1/Smad signaling pathways in mice model [189]. For
HBV related liver damage, FZHY recipe also showed good therapeutic effects in down-regulating
the levels of AST, ALT as well as HBV DNA concentration. A recent clinical trial study also showed
that FZHY capsule significantly decreases the ratio of TGF-beta1/BMP-7 mRNA in chronic viral
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Hepatitis B related fibrosis patients. FZHY could significantly decrease the ratio of TGF-beta1/BMP-7
(0.09 vs. 0.25, p < 0.05). In terms of pathological changes of the liver, the inflammatory activity for
G3 and fibrosis degree S3 in the FZHY group was significantly lower than that in the control group
(p < 0.05). In addition, the drug resistance related HBV YMDD variation in control group was higher
than in the FZHY group [190]. In a multicenter clinical study, FZHY capsule showed satisfactory effects
in treating chronic Hepatitis B related liver fibrosis with fewer adverse effects. Compared to another
traditional hepatoprotective formula, the Heluoshugan capsule, the FZHY capsule had a better effect
in suppressing inflammatory activity [191]. The FZHY tablet could inhibit the autocrine activation
pathway of hepatic stellate cells. This effect may be associated with the suppression of VEGF in hepatic
stellate cells [192]. As one of the patented TCM formulas, the phase III studies of FZHY tablet has just
started in the US in 2014, which will give more information on the safety and efficacy of the FZHY
tablet in different populations in the future.
3.2. Xiao Chai Hu Tang for Chronic Liver Disease Treatment
Xiao Chai Hu Tang (XCHT), a TCM herbal formula originally recorded in the ancient Chinese
classic book ’Shang-Han-Lun’, has been used to treat chronic liver disease for more than 2000 years in
China and some Asian countries, such as Japan where it has been approved as an ethical drug [193].
The main ingredients in this formula include Bupleurum, Scutellaria, ginseng, licorice, pinellia, ginger and
jujube. As one of the most popular TCM formulas, there are many studies showing that CHXT can
improve liver function and promote liver regeneration as well as prevent liver damage. According
to previous research, CHXT has been used to treat hepatitis, liver fibrosis and even hepatocellular
carcinoma. There are currently ongoing clinical trials for anti-Hepatitis C effect by XCHT at the
University of California, San Diego and Memorial Sloan-Kettering Cancer Center. Another research
group in Singapore also found that XCHT could inhibit the production of HBV, but the major
ingredients contributing to the activity are still not clear [194]. The previous study with children
as the patient group with HBV infection also showed improvement on HBeAg clearance rate by
SCHT [195]. In addition to the anti-HBV effect, another clinical trial showed that XCHT could improve
liver pathology in Hepatitis C patients. The results demonstrated that XCHT could down-regulate
the expression of AST and ALT in most of the Hepatitis C patients. Decrease of AST levels was
observed in 16/24 patients. Decrease of ALT levels was seen in 18/24 patients. Seven patients showed
decrease in viral load while 10 patients showed increase, and the results of the other seven patients
were indeterminate because of assay limitations. Moreover, the subsequent liver biopsy histology
also supported the hepatoprotective effect of XCHT in HCV patients [196]. To study the anti-fibrosis
effect of XCHT, one group used the bile duct ligation rats to evaluate the anti-fibrotic potential by this
herbal formula. Their results showed that XCHT could decrease cholestasis in bile duct ligation rats
and significantly down-regulate the collagen content. More importantly, XCHT exhibited remarkable
antifibrogenic effect through decreasing the expression of TIMP-1 and procollagen alpha1 types (I)
and (III) in liver [197]. Further studies by the same group demonstrated that XCHT could decrease
the serum fibrotic marker PIII NP in bile duct ligated rats through decreasing the expression of
platelet-derived growth factor and the transforming growth factor beta1. At the same time, XCHT
could induce the expression of TNF-alpha to suppress hepatic stellate cell proliferation and collagen
formation [198]. The role of SCHT in liver cancer is still controversial. Some studies found that XCHT
could prevent tumor formation in patients with hepatic cirrhosis, especially in those without HBV
infection [199]. However, another study demonstrated that 70-week administration of XCHT could
not prevent tumorigenesis in rats with spontaneous hepatocarcinogenesis [200].
3.3. Huanglian Jiedu Decoction in Liver Disease Treatment
The Huanglian Jiedu (HLJD) decoction originally appeared in “Essentials from the Imperial
Library” (Wai Tai Bi Yao) in DC 752. According to the basic theory of TCM, it is used for “Clearing
Heat from the Qi Level”. In Japan, HLJD decoction has been approved as a conventional drug for
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alcoholic and drug-induced liver disease. There are four substances in this TCM formula: Rhizoma
Coptidis, Scutellariae Baicalensis, Cortex Phellodendri and Fructus Gardeniae. Our recent findings showed
that HLJD decoction can inhibit liver tumor growth by suppressing the expression of eukaryotic
elongation factor-2(eEF2) in HCC cells. HLJD decoction could suppress HCC cell proliferation without
significant side-effects. In vivo study showed that it could inhibit tumor growth and angiogenesis
in xenografted mice. Further study of the mechanisms demonstrated that HLJD decoction could
inhibit the expression of nascent protein by suppressing the activation of eEF2 in liver cells. The major
active ingredients in HLJD decoction, geniposide, baicalin and berberine may synergistically activate
eEF2 kinase (eEF2K) and lead to eEF2 inactivation [201]. Similar results presented by another group
also confirmed that HLJD decoction was effective in other cancers [202]. The protective effects of
HLJD decoction in fatty liver disease in hyperlipidemia mice model might be mediated by damaged
tissue repair and immune-regulation of M2 macrophage subpopulations [203]. Another study of
hyperlipidemia rats showed different anti-steatosis mechanisms of HLJD and confirmed that the
activation of lipid metabolism enzyme and the increased expressions of LDLR and PPAR-gamma are
important in preventing liver steatosis in the rats [204].
3.4. Biejia Ruangan Tablets in Liver Disease Treatment
According to TCM theory, the Biejia Ruangan (BJRG) tablets can promote blood circulation and
soften hard masses in liver. The components of BJRG tablets include nine kinds of herbs (Rhizoma
curcumae, Radix Paeoniae rubra, Radix Angelica sinensis, Radix notoginseng, Radix codonopsis, Astragalus
membranaceus (Fisch.) Bunge, Placenta hominis, Radix isatidis, Fructus forsythia), an animal tissue (turtle
shell) and a complex of fungus and larva (Ophiocordyceps sinensis). BJRG tablets were the first Chinese
FDA approved herb compound for treatment of liver fibrosis. Over the past decades, the role of BJRG
tablet in prevention and treatment of fibrotic liver disease has been verified by many experiments
and clinical trials. BJRG tablet could inhibit the development of fibrosis by decreasing the mRNA
expressions of connective tissue growth factor in rats [205]. Another study using renal cells also
confirmed the anti-fibrosis effects of BJRG tablet and the mechanism may be related with its suppression
on TIMP-1 and type I and III procollagen expression [206]. In the rat liver fibrosis model induced by
carbon tetrachloride, there is a reduction in liver collagen deposition and improvement in hepatic injury.
The early cirrhosis related serum indicators such as PCIII, HA, laminin (LN) and collagen IV (CIV)
were obviously decreased. Further mechanism study revealed that the suppression of TGF-beta1 and
Smad3 expression may contribute to the hepatoprotective effects of BJRG tables [207]. A clinical trial
with 420 patients of HBV-related liver fibrosis found that 500 mg/day BJRG tablet may alleviate clinical
symptoms and hepatic fibrosis (55.67 percent and 81.67 percent vs. 15.8 percent and 60.00 percent,
p < 0.01) compared with the control group. Also, there is no obvious adverse effects detected
during the treatment [208]. In addition, another study found that increased dose of BJRG tablets
to 1000 mg/day showed a larger pharmacological and pharmacokinetic area under the curves (AUCs)
and better therapeutic effects than 500 mg/day or 1500 mg/day administration of BJRG tablet [209].
4. The Potential Side-Effects or Toxicity of Herbal Products in Chronic Liver Disease Treatment
Although most people consider herbal products as natural and safe agents, there have been
some clinical case-reports about side-effects or toxicity of herbal products in recent years. Some side
effects or toxicity of herbal medicines may constitute an acute exacerbation such as allergy, while some
agents may have chronic toxicity which require long-term accumulation such as some nephrotoxicity
herbs [210,211]. Herein, we reviewed the side-effects and toxicity of several conventional herbal
products in liver disease treatment.
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4.1. The Potential Side-Effects or Toxicity of Coptis Chinensis Franch and Berberine in Chronic Liver Disease
Treatment
The acute toxicity study in mice demonstrated that LD50 of Coptis chinensis Franch was
approximately 4.9 g/kg by oral and the LD50 values of berberine by intravenous injection and
intraperitoneal injection has been proved to be 9.0386 and 57.6103 mg/kg [212,213]. The most common
side effects of berberine include laxative, constipation, anaphylaxis and some skin allergies. One study
suggested that berberine may cause the degeneration of dopaminergic neuronal cells in Parkinson’s
disease rat model with long-term levodopa treatment. Berberine administration should be monitored
for Parkinson's disease patients with chronic L-DOPA treatment [214]. Some other studies believed
that berberine treatment for pregnant women may lead to hemolytic disease in newborns; berberine
treatment for children may lead to severe jaundice and acute hemolysis [215–218]. Prescriptions of
berberine have been prohibited in some countries such as the USA and Singapore, but it is still used
legally in China (including Hong Kong) in clinical practice.
4.2. The Potential Side-Effects or Toxicity of Glycyrrhizin in Chronic Liver Disease Treatment
Previous study has proved that glycyrrhizin can lead to pseudoaldosteronism which will cause
aldosteronopenia, hypokalemia, hypertension, and inhibited plasma renin activity [219]. Since
Glycyrrhiza uralensis Fisch raised the blood pressure in dose-related manner, previous study has proved
that consumption of 50 g of Glycyrrhiza uralensis Fisch (containing 75 mg glycyrrhetinic acid) per day
for two weeks can significantly raise the blood pressure. These results have important implications
for hypertension patients consuming Glycyrrhiza uralensis Fisch. Both in vitro and in vivo studies of
the licorice extracts exhibit estrogen-like activities which may lead to a high risk of heart disease in
women [220]. Another study also found that high dose administration of glycyrrhizin for pregnant
women will increase the premature birth rate [221]. For male patients, licorice extracts can lead to
down-regulation of serum testosterone secretion and cause impotency [222]. Other studies have
confirmed that high doses of glycyrrhizin can induce hypermineralocorticoid-like effects. Based on the
clinical evidence, the daily intake of glycyrrhizin should be lower than 0.2 mg/kg [223].
4.3. The Potential Side-Effects or Toxicity of Silymarine and Silybinin in Liver Disease Treatment
A phase I clinical trial in prostate cancer patients demonstrated that high dose silibinin
(13 g/day) may cause hyperbilirubinemia and increase alanine aminotransferase levels [224].
Other side effects include regulation of endocrine functions via blockade of estrogen receptor and
aryl hydrocarbon receptor (AhR) has also been reported. The estrogenic effects by silymarine should
also be paid attention to. An in vivo experiment on ovariectomized rats demonstrated that silymarine
can obviously inhibit the bone loss in ovariectomized rats with mild proliferative effects in uterus.
Generally, silymarine and silybinin have not shown any significant side effects or toxicity in previous
study, except for the above mentioned ones [225–227].
4.4. The Potential Side-Effects or Toxicity of Bupleurum Chinensis DC and Saikosaponins in Chronic Liver
Disease Treatment
Since the toxicity incidences of Xiao Chai Hu Tang have been reported in Japan, the side effects and
toxicity of Bupleurum have been the focus of much attention. Interstitial pneumonia can be induced by
combination treatment of interferon with Xiao Chai Hu Tang, and Bupleuri was believed to be the key
component in the decoction [228]. The single oral dose of Bupleuri in mice showed that the LD50 of
Bupleurum extracts was over 2000 mg/kg [229]. The most common side effects of Bupleurum include
increased bowel movements, intestinal gas, and drowsiness. Bupleurum could excessively activate the
immune system and might increase the symptoms of auto-immune diseases [230]. Alcohol eluent of
saikosaponins can induce liver damage by inhibiting the respiratory chain system of mitochondria
and suppressing liver energy metabolism [231]. Another study demonstrated that the consumption of
crude extracts of total saikosaponins may lead to liver damage, and the mechanism of this damage
28730
Int. J. Mol. Sci. 2015, 16, 28705–28745
may be attributed to oxidative damage [232]. Saikosaponins D also reduce the cell viability and cause
dramatic morphological changes in liver L02 cells. However, some may argue that the incorrect use
of Bupleuri may be the main cause of the adverse effects. The safe use of Bupleuri still needs further
investigation [233,234].
4.5. The Potential Side-Effects or Toxicity of Salvia Miltiorrhiza Bunge in Chronic Liver Disease Treatment
In 2010, the compound Danshen dripping pills became the first Chinese herbal medicine which
successfully completed US FDA Phase II clinical trials. As a major component of Salvia miltiorrhiza
Bunge, it should constitute a promising, safe medicinal plant for liver disease treatment. However, there
are still some side effects which should be paid serious attention to in clinical practice. Salvia miltiorrhiza
Bunge can inhibit hemostasis through suppressing platelet aggregation, enhancing fibrinolytic activity,
and inhibiting the extrinsic blood coagulation. At the same time, it could enhance the anticoagulant
effect by warfarin. Thus, for patients taking warfarin, Salvia miltiorrhiza Bunge treatment should be
avoided to decrease the risk of bleeding complications [235–237]. Some clinical research also found that
Salvia miltiorrhiza Bunge injection may lead to anaphylactic reaction on animal models, while negative
reaction was observed when treated with the liquid excipients of Salvia miltiorrhiza Bunge injection [238].
This may be attributed to some antigenic impurities which could not be removed completely in the
preparation process of Salvia miltiorrhiza Bunge injection. Other possible side effects include reduced
appetite, convulsions or itching. Some people may experience mental changes, stomach discomfort
and dystonia syndrome after Salvia miltiorrhiza Bunge treatment.
4.6. The Potential Side-Effects or Toxicity of Scutellaria Baicalensis Georgi in Chronic Liver Disease Treatment
Usually, treatment with Scutellaria baicalensis Georgi will not cause serious side effects. Occasionally,
it may induce lung inflammation, fever, or drowsiness. Chronic administration of Scutellaria baicalensis
Georgi may cause hepatotoxicity, which can lead to several clinical manifestation of liver disease. Some
clinical studies have confirmed that the association of medicinal herbs containing Scutellaria baicalensis
Georgi and Bupleurum chinense DC may induce liver fibrosis [239]. Some case reports in Japan and
Taiwan have revealed that patients exhibited acute drug-induced liver injury after treatment with
Xiao Chai Hu Tang, and Scutellaria baicalensis Georgi was believed to be one of the toxic ingredients
in this herbal formula [240,241]. Animal experiments also indicated that long term administration
of high dose wogonin (120 mg/kg) may lead to myocardial damage in rats [242]. Another study
found that the ingredients containing Scutellaria baicalensis Georgi were detected at different stages of
pregnancy in pregnant rats. This result demonstrated the potential risk of embryotoxicity may exist in
Scutellaria baicalensis Georgi treatment, and further basic and clinical studies are urgently needed for
this problem [243].
5. Conclusions
The current review provides a detailed and updated description of the most widely used herbal
medicine and herbal formulas used in alleviating chronic liver disease. It has been clearly described
that medicinal plants and phytochemicals can treat chronic liver disease by inhibiting oxidative
damage, suppressing fibrogenesis, eliminating virus infection, and preventing or inhibiting tumor
growth (Figure 2). For some medicinal plants, the active components still need to be further confirmed.
More randomized, placebo-controlled clinical trials are urgently needed to confirm the clinical efficacy
of this herbal medicine in chronic liver disease treatment. For the majority of medicinal herbs and
phytochemicals, the safety investigation is just as important as the efficacy investigation. In future
study, both basic research and clinical studies should be developed on the potential toxicity and side
effects of these herbal medicines. More medicinal plants and phytochemicals with safe performance
and significant efficacy are expected to be identified for use in chronic liver disease treatment in
the future.
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